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ABSTRACT 
 Protein-protein interactions regulate many biological systems. Understanding 
these interactions can provide insight into the function of proteins and the design of 
biological signaling networks, and can inform the development of more effective 
therapeutics. Protein-protein interactions can be described by thermodynamics, that is, 
the strength of binding, as well as by the distance between binding partners. In this thesis, 
I quantify protein-protein interactions in the Receptor Tyrosine Kinase (RTK) family, 
using novel quantitative fluorescence microscopy methods. In Chapter Three and Chapter 
Four, I characterize the formation of RTK homodimers using existing techniques. 
Specifically, I examine a subfamily of RTKs, known as the Fibroblast Growth Factor 
Receptors (FGFRs), in the presence of (i) pathogenic point mutations and (ii) activating 
ligands. In Chapter Five, I consider the formation of RTK heterodimers. I develop a 
method of measuring the thermodynamics of RTK heterodimer formation and apply it to 
the FGFR family. I also examine the effects of pathogenic point mutations on FGFR 
heterodimers. In Chapter Six, I study the interaction of RTKs with adapter proteins, an 
event that directly links RTKs to intracellular signaling networks. I develop and 
implement a procedure to measure the thermodynamics of this binding reaction, using the 
RTK Epidermal Growth Factor Receptor (EGFR) and the adapter protein Growth factor 
receptor-bound protein 2 (Grb2) as a model system. Overall, the work in this thesis 
demonstrates the utility of fluorescence microscopy for the quantitative characterization 
of protein-protein interactions in the membrane and reports previously unknown 
properties of the protein-protein interactions that regulate the RTK activation process.  
 
 iii   
 
Thesis Committee: Margarita Herrera-Alonso, Kalina Hristova (Reader), Feilim Mac 
Gabhann (Reader), Sua Myong, Marc Ostermeier (Chair) 
Alternates: James Spicer, Jeffrey Gray  
 iv   
 
ACKNOWLEDGMENTS 
 First, I would like to thank my advisor, Dr. Kalina Hristova, for the opportunity to 
perform research in her lab and for her guidance and support over the years. I learned so 
much about research during my years in the Hristova lab, and I know this experience will 
be useful as I move forward in my career. 
 I would also like to thank past and present members of the Hristova lab: Fozia 
Ahmed, Dr. Patrick Byrne, Jaynie Criscione, Dr. Lijuan He, Sarah Kim, Dr. Christopher 
King, Alexander Komin, Michael Paul, Dr. Jesse Placone, and Dr. Sarvenaz Sarabipour. 
These fellow Hristova lab members trained me in the lab, performed experiments that my 
work relies on, collaborated with me on new experiments, and engaged in many useful 
scientific discussions. 
 Next, I would like to thank my thesis committee, for their useful comments on 
this work. Special thanks goes to my readers, Dr. Feilim Mac Gabhann and Dr. Kalina 
Hristova. 
 During my doctoral studies, I dedicated a large chunk of time to developing my 
teaching skills. I would like to thank the Johns Hopkins University Teaching Academy 
for providing the forum for this. I would also like to thank the professors who have 
inspired me to become a better teacher, especially Dr. Eileen Haase and Dr. Orla Wilson. 
 Finally, and most importantly, I would like to thank my friends and family for 
their support throughout my academic career. An especially big thank you goes to my 
parents, Dario Del Piccolo and Suzanne Wheeler-Del Piccolo, for always encouraging me 
in my academic endeavors. Thanks also goes to my grandparents, for their support and 
inspiration over the years. I would not have made it to Johns Hopkins without the 
 v   
 
especial encouragement of my grandfather, Richard Wheeler. Lastly, I would like to 
thank my siblings, Chiara, Giulio, and Ivano, and friends, especially Zeinab Bakhiet, for 
always putting a smile on my face.  
  









To my parents, Dario Del Piccolo and Suzanne Wheeler-Del Piccolo 
  
 vii   
 
TABLE OF CONTENTS 
ABSTRACT ........................................................................................................................ ii 
ACKNOWLEDGMENTS ................................................................................................. iv 
DEDICATION ................................................................................................................... vi 
LIST OF TABLES .............................................................................................................. x 
LIST OF FIGURES ........................................................................................................... xi 
CHAPTER ONE Introduction ............................................................................................ 1 
Protein-Protein Interactions in the Plasma Membrane ................................................... 1 
Receptor Tyrosine Kinases (RTKs) ................................................................................ 1 
CHAPTER TWO Experimental Techniques ...................................................................... 6 
Molecular Biology .......................................................................................................... 6 
Cell Culture ..................................................................................................................... 7 
Model Membrane Systems ............................................................................................. 8 
Quantitative Fluorescence Microscopy Methods.......................................................... 10 
CHAPTER THREE Effect of Thanatophoric Dysplasia Type I Mutations on FGFR3 
Dimerization ..................................................................................................................... 18 
Thanatophoric Dysplasia Type I ................................................................................... 18 
Homodimerization Model ............................................................................................. 19 
Results ........................................................................................................................... 23 
Discussion ..................................................................................................................... 27 
 viii   
 
CHAPTER FOUR Conformational Changes in FGFR1 and FGFR2 Homodimers in 
Response to the fgf Ligands that Regulate Embryonic Limb Development .................... 37 
Receptor-Ligand Interactions and Embryonic Limb Development .............................. 37 
Fully Liganded Homodimer Model .............................................................................. 39 
Results ........................................................................................................................... 41 
Discussion ..................................................................................................................... 45 
CHAPTER FIVE A New Method to Study Heterodimerization of Membrane Proteins 
and its Application to Fibroblast Growth Factor Receptors ............................................. 61 
RTK Heterodimerization and the FGFRs ..................................................................... 61 
Heterodimerization Model ............................................................................................ 64 
Results ........................................................................................................................... 70 
Discussion ..................................................................................................................... 76 
CHAPTER SIX Characterization of the Interaction Between EGFR and Grb2 in Live 
Cells .................................................................................................................................. 96 
RTK-Adapter Protein Interactions and EGFR-Grb2 .................................................... 96 
Model to Describe RTK-Adapter Protein Interactions ................................................. 98 
Results ......................................................................................................................... 101 
Discussion ................................................................................................................... 108 
CHAPTER SEVEN Conclusions .................................................................................... 117 
REFERENCES ............................................................................................................... 119 
 ix   
 
CURRICULUM VITAE ................................................................................................. 131 
  
 x   
 
LIST OF TABLES 
Table 3-1. Optimal parameters describing homodimerization of WT FGFR3 and the TD 
mutants. ............................................................................................................................. 36 
Table 4-1. FGFR1 and FGFR2 Intrinsic FRET and inter-fluorophore distance in the 
presence of five activating ligands. ................................................................................... 60 
Table 5-1. Optimal parameters describing FGFR homodimerization and 
heterodimerization. ........................................................................................................... 93 
Table 5-2. Effects of the Achondroplasia and Crouzon syndrome mutations on FGFR 
heterodimerization. ........................................................................................................... 95 
  
 xi   
 
LIST OF FIGURES 
Figure 1-1. The canonical and emerging models of RTK activation. ................................. 5 
Figure 2-1. Live cell-derived model membrane systems. ................................................. 13 
Figure 2-2. Diagrams describing Förster Resonance Energy Transfer (FRET) and the 
YFP-mCherry FRET pair. ................................................................................................. 14 
Figure 2-3. Quantitative FRET microscopy methods. ...................................................... 16 
Figure 3-1. Cartoon representation of the species present in homodimer FRET 
experiments. ...................................................................................................................... 30 
Figure 3-2. FRET efficiency versus acceptor concentration for wild-type FGFR3 and the 
TD mutants........................................................................................................................ 31 
Figure 3-3. Donor concentration versus acceptor concentration for WT FGFR3 and the 
TD mutants........................................................................................................................ 33 
Figure 3-4. Dimeric fraction times Intrinsic FRET, versus total receptor concentration for 
WT FGFR3 and the TD mutants. ...................................................................................... 34 
Figure 3-5. Dimeric fraction versus receptor concentration for WT FGFR3 and the TD 
mutants. ............................................................................................................................. 35 
Figure 4-1. Cartoon representation of changes in Intrinsic FRET in liganded homodimers.
........................................................................................................................................... 47 
Figure 4-2. FGFR1 homodimerization in the presence of five activating ligands. ........... 52 
Figure 4-3. FGFR2 homodimerization in the presence of five activating ligands. ........... 58 
Figure 4-4. Comparison of FGFR1 and FGFR2 Intrinsic FRET in the presence of five 
activating ligands. ............................................................................................................. 59 
 xii   
 
Figure 5-1. A cartoon representation of the receptor species present in heterodimer FRET 
experiments. ...................................................................................................................... 82 
Figure 5-2. Theoretical predictions of the heterodimerization model, as a function of the 
concentration of the two receptors. ................................................................................... 84 
Figure 5-3. Vesicle FRET data for the (A-C) wild-type and (D-I) mutant FGFR 
heterodimers. ..................................................................................................................... 88 
Figure 5-4. Experimentally determined and theoretically predicted heterodimer 
concentrations [XY], as a function of the two receptor concentrations. ........................... 89 
Figure 5-5. Total dimer fractions for wild-type and mutant FGFR heterodimers. ........... 90 
Figure 5-6. Optimal parameters from the fit of the heterodimerization model to 
experimental FGFR data. .................................................................................................. 92 
Figure 6-1. The thermodynamic cycle describing the RTK activation process. ............. 111 
Figure 6-2. FRET efficiency for possible geometries of the dimer-adapter protein 
complex. .......................................................................................................................... 112 
Figure 6-3. FRET data for the interaction between EGFR and Grb2, under saturating 
ligand conditions. ............................................................................................................ 114 




 1   
 
CHAPTER ONE Introduction 
Protein-Protein Interactions in the Plasma Membrane 
 Protein-protein interactions regulate many biological systems, and are the focus of 
this thesis. The current understanding of biological processes, including protein-protein 
interactions, is often qualitative. However, a quantitative understanding of biology, and 
protein-protein interactions, is expected to provide insight into the design of biological 
signaling networks and protein function, and to inform the development of more effective 
therapeutics (1-6). Here, we seek to quantify the thermodynamics of protein-protein 
interactions in the plasma membrane. 
 Membrane proteins are notoriously difficult to study. They have both 
hydrophobic and hydrophilic domains and are often glycosylated. These physiochemical 
properties render methods used to study the interactions of soluble proteins less effective 
for membrane proteins, if they can be used at all (7-9). Hence, knowledge of membrane 
proteins, quantitative or otherwise, lags behind that of soluble proteins. However, 
membrane proteins, which comprise approximately 30% of all proteins, play a key role in 
many cellular processes. They regulate communication across the membrane, initiate 
many signaling networks, and represent a major drug target (4,6-9). Recent research has 
focused on developing new methods for the study of membrane proteins, and in this 
thesis, I will both use and contribute to this growing toolbox. 
Receptor Tyrosine Kinases (RTKs) 
 Receptor Tyrosine Kinases (RTKs) are the second largest class of membrane 
proteins. There are 58 different RTKs, which can be classified into 20 families based on 
sequence similarity. These cell surface receptors play critical roles in many biological 
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processes, including growth, development, communication, and movement, and are often 
implicated in developmental disorders and cancers (4,10-13). In this thesis, I study 
protein-protein interactions in the context of four different RTKs: FGFR1, FGFR2, 
FGFR3, and EGFR. 
RTK Activation 
 A prototypical RTK consists of a ligand-binding extracellular (EC) domain, a 
single-pass transmembrane (TM) domain, and a tyrosine kinase intracellular (IC) domain 
(4,10-12,14-17). The competing models for RTK activation are shown in Figure 1-1. 
 Figure 1-1, Panel A is a cartoon representation of the canonical model describing 
RTK activation. In the absence of ligand, receptors exist as monomers, and ligand 
binding cross-links two receptors into a dimer complex. Dimer formation brings the IC 
domains into close proximity, allowing receptors to cross-phosphorylate each other. 
Phosphorylated receptors, in turn, initiate downstream signaling cascades such as the 
MAPK, STAT, PKC, and PI3K pathways, and these biochemical networks determine 
functional outcomes (4,10-12). 
 Figure 1-1, Panel B diagrams the emerging model of RTK activation. Recent 
work has shown that RTKs form dimers even in the absence of ligand (18,19), suggesting 
that the simple unliganded monomer versus liganded dimer framework may not fully 
describe the RTK activation process. The emerging model of RTK activation considers 
monomers, unliganded dimers, and liganded dimers. Unliganded dimers are believed to 
prime the receptors for complete activation and to exhibit partial activity. In particular, 
the activity of unliganded dimers has been implicated in the progression of 
developmental disorders and cancers (4,10,15,20,21). Ligand binding to unliganded 
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dimers is proposed to induce a conformational change that leads to full activation of the 
RTK (18,19). The function of active dimers in the canonical and emerging models is the 
same: the IC domains cross-phosphorylate each other, which in turn activates 
downstream signaling cascades.  
Fibroblast Growth Factor Receptors 
 The Fibroblast Growth Factor Receptor (FGFR) family of RTKs regulates 
development of the skeletal system, and has also been implicated in many cancers 
(13,14,22-24). There are four receptors in this family―FGFR1, FGFR2, FGFR3, and 
FGFR4―and I study FGFR1, FGFR2, and FGFR3, the three receptors required for 
proper skeletal development (14). The FGFRs bind 18 ligands, known as fibroblast 
growth factor (fgfs). FGFR dimers have a 1:1 ratio of receptor to ligand and are believed 
to have a symmetric structure (14,25). 
 Receptors in the FGFR family have a characteristic architecture. The EC domain 
consists of three immunoglobin-like domains (DI, DII, and DIII), with an acid box 
between DI and DII, and a flexible linker between DII and DIII. In the absence of ligand, 
the EC domain inhibits dimer formation (26). Ligands bind to receptors via specific 
interactions with DII, the linker, and DIII (13,14,22), and dimerization occurs through 
inter-receptor contacts. The EC domain is followed by a TM domain, which has been 
shown to promote dimer formation (26,27). The FGFR IC domain is a tyrosine kinase 
that is thought to adopt an autoinhibitory conformation in the absence of ligand (13,22).  
Epidermal Growth Factor Receptor 
 The Epidermal Growth Factor Receptor (EGFR) is a member of the ErbB family 
of RTKs. While other families of RTKs are often linked to specific tissue types, the 
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ErbBs have been shown to regulate the development of a wide variety of tissue types. 
EGFR was the first RTK directly linked to human cancers and thus has been studied 
more extensively than many other RTKs (4,10,11,15-17,28). There are at least 7 ligands 
that bind EGFR. Like the FGFRs, EGFR binds these ligands in a 1:1 ratio of receptors to 
ligands, but the EGFR dimer is notable for its asymmetric structure (5,10). 
 The EC domain of EGFR is composed of four domains: DI and DIII are leucine-
rich domains, and DII and DIV are cysteine-rich domains. In the absence of ligand, the 
EC domain adopts a closed conformation, mediated by intra-receptor contacts between 
DII and DIV. Ligand binding to DI and DIII exposes the so-called dimerization interface 
of DII, which participates in inter-receptor contacts and the formation of dimers 
(4,10,11,15,16,28,29). The EC domain is followed by a TM domain, which is also 
expected to promote dimerization (30). The EGFR IC domain consists of a tyrosine 
kinase domain followed by a long tail. The EGFR IC domain is unique in that it forms an 
asymmetric dimer and that the phosphorylation sites linking receptor activity to 
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CHAPTER TWO Experimental Techniques 
 The experiments described in Chapter Three, Chapter Four, Chapter Five, and 
Chapter Six rely on the same or very similar molecular biology, cell culture, and FRET 
microscopy protocols. The details of these experimental procedures are compiled in this 
chapter. 
Molecular Biology 
 Traditional cloning techniques were employed in this work. That is, we use 
polymerase chain reaction to replicate DNA sequences, and restriction enzymes and 
ligations to assemble pieces of DNA. Following assembly, all plasmids were amplified 
using DH5α E. coli cells. 
 In Chapter Three, Chapter Four, and Chapter Five, we study the FGFR subfamily 
of RTKs. Since the lab has previously studied the FGFRs quite extensively, the wild-type 
FGFR1, FGFR2, and FGFR3 plasmids were generated by other lab members (18,26). 
These plasmids code for the EC and TM domains of the receptor, followed by a flexible 
(GGS)5 linker and a fluorescent protein (eYFP or mCherry). In Chapter Three and 
Chapter Five, we study pathogenic point mutations in FGFR3. The mutations for 
Achondroplasia (32) and Crouzon Syndrome with acanothsis nigricans (33) were 
engineered into the wild-type FGFR3 plasmids by other lab members. The Thanatophoric 
Dysplasia Type I mutations were introduced using the Agilent Technologies QuikChange 
II mutagenesis kit, according to the manufacturer's instructions (34). 
 In Chapter Six, we study the interaction between EGFR and Grb2. The EGFR 
gene in the pSSX vector (35) was a kind gift from Daniel Leahy. We inserted the genes 
for a GGS linker and mTurquoise between the KpnI and NotI restriction sites of the 
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pSSX plasmid, in order to fluorescently label the C-terminus of the receptor. The empty 
pSSX vector and the Grb2 gene were kind gifts from Daniel Leahy and Jin Zhang, 
respectively. First, genes for the GGS linker and YFP were inserted into the empty pSSX 
vector, between the XbaI and NotI restriction sites. Next, we added a Kozak sequence 
and Grb2 between the BamHI and XbaI restriction sites, to generate a plasmid coding for 
Grb2 followed by a short flexible linker and a fluorescent protein.  
Cell Culture 
 Chinese Hamster Ovary (CHO) cells were used for all cell studies in this thesis. 
These epithelial-like cells are commonly used to express recombinant proteins (36-38). 
Benefits of CHO cells include their high protein expression, the similarity of their post-
translational protein modifications to those of humans, and their short doubling time. 
CHO cells are particularly well-suited to the experiments in this thesis. Namely, they 
have been shown to not express the FGFRs or EGFR, so the possibility that our 
recombinant RTKs interact with natively expressed receptors need not be considered. 
 CHO cells were maintained in an incubator at 37oC with 5% carbon dioxide. 
Culture media consisted of Dulbecco's Modified Eagle's Medium supplemented with 1.8 
g/L glucose, 1.5 g/L sodium bicarbonate, 10% fetal bovine serum, and 1 mM 
nonessential amino acids. Cells were passed every other day. 
 Transient transfections of CHO cells were performed using FugeneHD, at a ratio 
of 3 uL of transfection reagent per 1 ug of plasmid. Transfections proceeded for 24 hours 
prior to an experiment, which allowed for receptors to be synthesized, trafficked to the 
membrane, and glycosylated. 
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 The experiments described in Chapter Three and Chapter Five were performed in 
the absence of ligand. In Chapter Four, we worked with five fgf ligands. fgf4, fgf8, fgf9, 
and fgf16 were all purchased from R&D Systems, and fgf18 was purchased from 
Peprotech. The EGF ligand used in Chapter Six was a kind gift from Daniel Leahy. All 
experiments in the presence of ligand were performed under saturating conditions. 
Model Membrane Systems 
 The plasma membrane is hydrophobic barrier that separates the cell from its 
environment. It is a heterogeneous and dynamic system composed of lipids and proteins, 
with an asymmetrical composition between the two leaflets (8,39,40). Recent 
experiments have overturned the notion that the membrane is a smooth surface, instead 
showing that the plasma membrane of a resting cell is highly wrinkled and folded 
(41,42). Organization of membrane structure and local lipid and protein composition are 
regulated by the cytoskeleton; by lipid-lipid, lipid-protein, and protein-protein 
interactions; and perhaps by the formation of lipid rafts (8,39). These complexities 
preclude direct quantification of protein-protein interactions in native membranes (7-
9,40).  
 In this thesis, we instead work with two model membrane systems (41,43). Both 
models are derived from live CHO cells, so they retain many of the properties of native 
membranes. Both models mimic the lipid and protein content of the membrane of the 
cells from which they are derived (44,45). Additionally, receptors are trafficked to the 
membrane by the native cellular machinery, so they undergo all relevant post-
translational modifications, including glycosylation (37,38). However, these models 
simplify the plasma membrane system enough to enable quantitative measurements of 
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protein-protein interactions. Most importantly, the membrane is stretched out, eliminating 
the wrinkling and folding of live cells, which enables direct measurement of receptor 
concentrations and interactions in the membrane (46). Additional details about the two 
model systems―cell-derived vesicles and swollen cells―are given below. 
Cell-derived Vesicles 
 Cell-derived vesicles are spheres of plasma membrane that can be used as a model 
membrane system (40,43,45,47,48). Vesicle production is typically induced using 
chemicals or osmotic pressure buffers (43,45,47-49). Here, we employ an osmotic 
pressure-based technique to derive vesicles from the plasma membrane of live CHO 
cells. We reported this method, known as the chloride salt vesiculation protocol, in 2012 
(43). Briefly, cells are rinsed with a hypotonic rinse buffer and then incubated in a 
hypertonic buffer, which causes the cells to release large plasma membrane vesicles into 
solution. The biological mechanism through which cells generate and release these large 
vesicles remains unknown (40).  
 Vesicles derived from CHO cells using the chloride salt vesiculation technique 
are similar in size to live cells (they have an average diameter of 17.2 μm) (43) and have 
a lipid content that matches the cells from which they are derived (44). However, these 
vesicles lack both the cytoplasm and cytoskeleton (44). Vesicles are an equilibrium 
model membrane system, so the concentration of RTKs and other proteins and lipids is 
fixed. Figure 2-1, Panel A shows two fluorescent images of vesicles derived from CHO 
cells expressing FGFR3 labeled by a fluorescent protein. 
Swollen Cells 
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 Swollen cells are live cells that have been treated with a hypotonic buffer, causing 
them to expand. Specifically, the buffer consists of one part cell culture media to nine 
parts DI water and has a pH of 7.4. Swelling cells using this hypotonic buffer is a 
reversible process (41). The swelling process stretches out the membrane of the cell, so 
that it is no longer folded and wrinkled (41,46). A stretched membrane is important for 
accurate measurement of fluorophore concentrations and FRET efficiency using our 
quantitative FRET microscopy techniques (46). Swollen cells retain both the cytoplasm 
and cytoskeleton, and we expect the lipid and protein content to be identical to that of 
unswollen cells. Like vesicles, swollen cells are an equilibrium model membrane system, 
because the tension in the membrane of a swollen cell inhibits endocytosis (50). In Figure 
2-1, Panel B, we show a fluorescent image of a swollen CHO cell expressing EGFR 
labeled with a fluorescent protein. 
Quantitative Fluorescence Microscopy Methods 
 Förester Resonance Energy Transfer (FRET) is a molecular-level physical 
process that is often employed to report on protein-protein interactions (51,52). FRET 
relies on the special properties of fluorescent molecules, namely, their ability to undergo 
radiative decay. Radiative decay is a process in which relaxation of electrons from the 
excited state to the ground state is accompanied by photon emission. The excitation and 
emission wavelengths of a fluorescent molecule depend on the energy differences 
between the ground and excited electron states and vary from fluorophore to fluorophore. 
In FRET, the emission wavelength of one fluorophore (the "donor") matches the 
excitation wavelength of the second fluorophore (the "acceptor"), such that photons 
emitted from the donor molecule will excite the acceptor molecule, when the two are in 
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close proximity. The efficiency of this process is highly distance dependent and is 
described by the following: 
    




   (2-1) 
where E is the FRET efficiency, d is the distance between the acceptor and donor, and R0 
is the Förster radius of the FRET pair. Figure 2-2, Panel A diagrams the excitation and 
emission wavelengths for yellow fluorescent protein (YFP) and the red fluorescent 
protein mCherry. Panel B shows FRET efficiency as a function of distance when YFP is 
the FRET donor and mCherry is the FRET acceptor. The YFP-mCherry FRET pair is 
used in Chapter Three, Chapter Four, and Chapter Five. 
 In this thesis, we use FRET, in conjunction with fluorescence microscopy, to 
report on protein-protein interactions in the RTK family. We use two novel fluorescence 
microscopy techniques, both of which ultimately measure three quantities: the donor 
concentration, the acceptor concentration, and the FRET efficiency. 
Quantitative Imaging-FRET (QI-FRET) 
 Quantitative Imaging-FRET (QI-FRET) is a fluorescence microscopy technique 
developed in the Hristova lab to measure the thermodynamics of protein-protein 
interactions in plasma membranes (53-55). QI-FRET is performed using a Nikon Eclipse 
scanning confocal microscope and a 60x objective. The cross-section of vesicles or 
swollen cells is imaged in each of three channels, corresponding to the donor, the 
acceptor, and FRET efficiency. The microscope is calibrated using solutions of 
fluorescent protein, so that fluorescence intensity and fluorophore concentration can be 
directly correlated. This calibration is used to convert fluorescence intensity along the 
membrane in each channel to donor concentration, acceptor concentration, and FRET 
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efficiency. A representative cell-derived vesicle and its QI-FRET analysis are shown in 
Figure 2-3, Panel A. 
Fully Quantified Spectral Imaging (FSI) 
 Fully Quantified Spectral Imaging (FSI) is another fluorescence microscopy 
technique developed in the Hristova lab and also reports on protein-protein interactions in 
plasma membranes (46). The FSI method utilizes the Aurora Spectral Technologies 
OptiMiS system (56), attached to a two-photon microscope (51). The OptiMiS system 
yields a full fluorescence spectra for every pixel in an image, and the two-photon 
microscope facilitates high spatial resolution and minimizes photobleaching of 
fluorophores (57). In the FSI method (46), the cross-section of a vesicle or swollen cell is 
imaged twice, following excitation of the donor and the acceptor, respectively. The 
microscope system is calibrated by imaging i) solutions of fluorescent protein and ii) 
vesicles or swollen cells transfected with only the donor or only the acceptor. This 
calibration establishes the relationship between fluorophore concentration and 
fluorescence intensity, and allows for pixel-level deconvolution of fluorescence spectra 
along the membrane into donor concentration, acceptor concentration, and FRET 
efficiency. A representative swollen cell and its FSI analysis is shown in Figure 2-3, 
Panel B. 
  






























Figure 2-1. Live cell-derived model membrane systems. 
Fluorescent images of (A) cell-derived vesicles and (B) swollen cells. Both model 
membranes are derived from CHO cells that have been transfected with RTKs labeled 
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contributions are used to measure three quantities in each region of interest: the donor 
concentration, the acceptor concentration, and the FRET efficiency. This cell is from the 
experiments described in Chapter Six, where we examine the interaction between a RTK 
(on the membrane) and an adapter protein (in the cytoplasm). 
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CHAPTER THREE Effect of Thanatophoric Dysplasia Type I Mutations on 
FGFR3 Dimerization 
This research was originally published in the Biophysical Journal. Nuala Del Piccolo, 
Jesse Placone, and Kalina Hristova. Effect of thanatophoric dysplasia type I mutations on 
FGFR3 dimerization. Biophysical Journal. 2015; 108: 272-278. 
The text reproduced here has been revised to match the style of this thesis. 
Thanatophoric Dysplasia Type I 
 Thanatophoric dysplasia type I (TDI) is a lethal human skeletal growth disorder 
with a prevalence of 1 in 20,000 to 1 in 50,000 births.  It is one of the most severe of the 
skeletal dysplasias and typically leads to neonatal death (58-60). Typical features of the 
TDI phenotype include shortened limbs with bowed femurs and cloverleaf skull 
deformities. 
 TDI is known to arise due to five different mutations, all involving the 
substitution of an amino acid with a cysteine in Fibroblast Growth Factor Receptor 3 
(FGFR3): Arg248Cys, Ser249Cys, Gly370Cys, Ser371Cys and Tyr373Cys (61-63). Of 
these, Arg248Cys and Tyr373Cys account for 60 to 80% of all cases of TDI. These 
cysteine mutations have been shown to increase the phosphorylation and activation of the 
receptor in the absence of ligand (64,65), increase downstream extracellular signal-
related kinase signaling (66), and increase BaF3 cell proliferation (67). The mutations 
compromise the downregulation of activated FGFR3 dimers in the plasma membrane 
(68) and increase retention of FGFR3 dimers in the endoplasmic reticulum (69). 
Furthermore, it has been shown that overactivation of FGFR3 leads to the inhibition of 
chondrocyte proliferation during development, which impedes bone growth (23,70). 
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 FGFR3 is a receptor tyrosine kinase (RTK) which consists of an extracellular 
(EC) domain involved in ligand binding, a single-pass transmembrane (TM) domain, and 
an intracellular (IC) tyrosine kinase domain. Like all RTKs, FGFR3 functions via a 
lateral dimerization process that brings the kinase domains into close proximity so that 
they can phosphorylate and activate each other (62,71-73). 
 Mutations to cysteine residues in RTKs have been proposed to cause cross-linking 
of the receptors via disulfide bonds, thereby inducing constitutive dimerization and 
activation (64,74-76). However, the effect of the mutations on unliganded RTK dimer 
stability has never been characterized in quantitative terms. In this study, we characterize 
the effect of three TDI mutations, Arg248Cys, Ser249Cys, and Tyr373, on the stability 
and the structure of FGFR3 dimers. We accomplish this by using a Förster Resonance 
Energy Transfer (FRET)-based technique (26,54) that yields dimerization free energies of 
glycosylated RTKs and reports on structural differences between RTK dimers.  
Measurements are performed in plasma membrane vesicles derived from CHO cells with 
the use of a novel osmotic stress vesiculation method (43). We find that the three TDI 
mutations cause a modest stabilization of the FGFR3 dimer. We also observe modest 
structural perturbations in the FGFR3 dimer because of the mutations.   
Homodimerization Model 
 The two-state thermodynamic model describing the equilibrium between RTK 
monomers and RTK dimers is given by the following reaction scheme: 
    
 
    (3-1) 
where M and D denote monomers and dimers, respectively. K is the homodimer 
association constant, which can be expressed as: 
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  (3-2) 
where the bracket notations indicate two-dimensional concentrations. This association 
constant can be used to calculate the Gibbs free energy of dimerization: 
            (3-3) 
where the standard state is defined as 1 square nanometer per receptor (54). Receptor 
concentration is constant in vesicles, so the law of mass conservation can be applied: 
               (3-4) 
where T is the total number of receptors. Total dimer fraction can be written as 
    
    
   
  (3-5). 
Together, the equilibrium equation and the mass conservation equation describe the 
process of RTK homodimer formation. This system of equations can be solved so that the 
homodimerization model can be described with a single equation: 
    
 
   
     
 
  
               (3-6). 
Interpretation of Homodimer FRET Data 
 Figure 3-1 is a cartoon representation of the monomer and dimer species present 
in homodimer FRET experiments. The measured FRET efficiency depends on both the 
proximity FRET efficiency, which arises due to the random close approach of donors and 
acceptors in the two-dimensional membrane, and the dimer-specific FRET efficiency, 
which occurs due to the formation of homodimers containing both a donor and an 
acceptor. We correct for the proximity FRET as discussed in (77) and are left with the 
dimer-specific FRET efficiency, ED.  Dimer-specific FRET in each vesicle can be written 
as: 
             (3-7) 
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where fD is the dimeric fraction, xA is the fraction of acceptors in a vesicle, and Ẽ is the 
so-called Intrinsic FRET. Equation 3-7 assumes that the probabilities for the formation of 
donor-donor, donor-acceptor, acceptor-donor, and acceptor-acceptor dimers (see Figure 
3-1) are the same. This is a reasonable assumption because we use monomeric 
fluorescent proteins that are not expected to affect the propensity for dimer formation.  
 The Intrinsic FRET is a structural parameter that depends on the separation and 
orientation of the donor and the acceptor in a dimer. The dependence of the Intrinsic 
FRET, or Ẽ, on the distance between the fluorescent proteins in the dimer is given by the 
following: 
     




   (3-8) 
where d is the distance between the acceptor and the donor in the dimer, and R0 is the 
Förster radius of the FRET pair (54). For eYFP and mCherry, R0 is 53.1 Å, which we 
measured in previous work (46,54), under the assumption of free fluorophore rotation. 
The assumption of free rotation of the fluorescent proteins in these experiments is 
justified, because they are attached to the receptors via long flexible linkers (78). Since Ẽ 
is generally unknown (because the structures of the wild-type and the mutants are 
unknown and may be different), the quantity considered when fitting the homodimer 
model to experimental FRET data is given by the following: 
       
  
  
  (3-9). 
 Predictions for dimeric fractions, generated by Equation 3-6, are fit to the 
experimental data, measured according to Equation 3-9, while varying the two unknown 
parameters, namely the dimerization constant, K, and the Intrinsic FRET, Ẽ. A least-
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squares two parameter fitting procedure for K and Ẽ is performed for each data set using 
MATLAB. 
 The best fit K and Ẽ parameters are used to calculate additional characteristics of 
the homodimer. From the dimerization constant, we can use Equation 3-3 to calculate the 
dimer stability. The Intrinsic FRET allows us to calculate the distance between the 
fluorescent proteins in each homodimer, according to Equation 3-8. 
Statistical Analysis 
 A χ2 analysis is used to compare the wild-type data set with each of the TDI 
mutant data sets. In particular, we test the null hypothesis that the data sets being 
compared are not different. For each data set, the results are averaged within bins of 
5x104 receptors/nm2. These bins are compared with each other in a pairwise fashion using 
the following equation: 
      
                
   
 
 
  (3-10) 
where i is the number of bins, and avgwt,i and avgmut,i are the average values in the wild-
type and mutant bins, respectively. The standard error for each bin, SEi, is defined as 
follows: 
              
 
          
 
  (3-11) 
where SEwt,i and SEmut,i are the standard errors in the wild-type and mutant bins, 
respectively. Finally, using these χi2 values and df, the degrees of freedom, equal to the 
number of bins minus one, we calculate the reduced χ2 value as follows: 




  (3-12). 
We determine p-values using a χ2 table (79). The cutoff for significance is p < 0.05. 
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 Additional statistical analysis is used to compare the K and Ẽ parameters 
determined for the wild-type with those determined for each of the mutants. We test the 
null hypothesis that the average values are not different from each other. We use 
GraphPad Prism to perform analysis of variance (ANOVA) and t-tests, and to calculate p-
values. 
Results 
 In the experiments reported in this study, we characterized the unliganded 
dimerization of wild-type FGFR3 and three TDI mutants in plasma membrane-derived 
vesicles. Experiments were performed with receptors in which the intracellular domains 
were substituted with fluorescent proteins (eYFP or mCherry) to allow for FRET 
detection. 
 The fluorescent proteins were attached to the TM domains via flexible (GGS)5 
linkers. The (GGS)5 linker has been shown to be unstructured and behave like a random 
coil with an apparent radius of about 45 Å (78), when fused between two proteins. It has 
been further shown that models that assume free rotations of the fluorescent proteins 
attached to the two sides of the linker correctly predict the measured FRET efficiency 
(78). Based on these studies, it can be safely assumed that the fluorophores are rotating 
freely, and the distance between the fluorophores depends only on the points of 
attachment of the linkers to the protein, in this case the distance between the C-termini of 
the TM domains in the dimer. 
 To obtain vesicles containing FGFR3, we first co-transfected CHO cells with 
plasmids encoding for either the wild-type or the TDI mutants linked to eYFP and 
mCherry. Since the receptors are produced in CHO cells, they undergo all required post-
 24   
 
translational modifications, including full glycosylation. Following transfection, plasma 
membrane-derived vesicles were produced from the CHO cells using an osmotic stress 
method (43). Such vesicles do not have the actin cytoskeleton (45,47,48), which is known 
to play an important role in maintaining the lateral heterogeneity of biological 
membranes. Consistent with this, we invariably observe homogeneous distribution of 
fluorescence throughout the vesicle membrane (43,54). 
The vesicles were transferred to chambered cover-glass slides for image 
acquisition. They were imaged using a Nikon Eclipse C1 laser scanning confocal 
microscope. Each vesicle was imaged using three separate scans: a donor scan, a FRET 
scan, and an acceptor scan, as described in previous publications (32,33,53,80,81). 
Following image acquisition, vesicles were processed using an in-house MATLAB script 
(54). For each scan of every image, this program identified the membrane of the vesicle 
and fit the fluorescence intensity across the membrane with a Gaussian function (see 
Figure 2-3). Solutions of purified fluorescent proteins were used to calibrate the donor 
and acceptor fluorescence intensities as described previously (53). The FRET efficiency, 
the donor concentration, and the acceptor concentration were determined in each vesicle 
using the QI-FRET method (54,55). 
 In Figure 3-2, we show the FRET efficiencies per vesicle plotted against the 
acceptor concentration in that vesicle; each data point corresponds to a single vesicle. 
Data for the wild-type, Arg248Cys, Ser249Cys, and Tyr373Cys constructs are shown as 
open blue diamonds, filled red squares, filled green triangles, and filled purple circles, 
respectively. Each data set contains ~500+ single vesicles and was collected in more than 
10 independent experiments.  The solid black line in Figure 3-2 indicates the expected 
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FRET efficiency due to the random approach of donors and acceptors (see (77) for 
details). This proximity FRET contribution occurs because the fluorophores are confined 
to the two-dimensional membrane and has been discussed in the literature (77,82,83). 
The data fall well above this line, which indicates that the FRET we observe is due to 
specific interactions between the receptors. Furthermore, FRET efficiencies measured for 
the mutants are higher than the efficiencies for the wild-type. Therefore, the TDI 
mutations have an effect on FGFR3 dimerization.  
 FRET due to FGFR3 dimerization was determined by correcting for proximity 
FRET (which depends only on the acceptor concentration (77)) from the measured 
FRET. Then, we calculated the product of the dimeric fraction in the vesicle, fD, and the 
Intrinsic FRET, Ẽ, using Equation 3-9. To do so, we need the donor and the acceptor 
concentrations in each vesicle, shown in Figure 3-3. As discussed previously (54), these 
are two-dimensional concentrations in the membrane. The dimerization constant is a 
thermodynamic parameter which describes the propensity for dimerization in quantitative 
terms. The Intrinsic FRET, Ẽ, is a structural parameter which is very sensitive to changes 
in dimer structure, since FRET efficiency falls off with the sixth power of distance 
between fluorophores as seen in Equation 3-8.  The product of these two parameters, fDẼ, 
is plotted in Figure 3-4 as a function of the total receptor concentration, after averaging 
the data in bins of width 5x104 receptors/nm2. 
Using χ2 analysis (79), we performed a pairwise comparison of the binned wild-
type data set with each of the mutant data sets. Reduced χ2 values of 133.97, 55.33, and 
28.91 were calculated for the Arg248Cys, Ser249Cys, and Tyr373Cys mutants, 
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respectively. The corresponding p-values were all <0.001 and the observed differences 
were highly statistically significant for all the mutants. 
Since the experimental data in Figure 3-4 depend on both the dimerization 
constant, K, and the Intrinsic FRET, Ẽ, we used Equation 3-9 and performed a two 
parameter fit on each data set to determine the optimal K and Ẽ values for each construct.  
The results of the fit are shown in Table 3-1, along with their standard errors (67% 
confidence intervals). Next, the K and Ẽ values were used to calculate additional 
characteristics of the dimer; these results are also shown in Table 3-1. The dimerization 
Gibbs free energy (dimer stability, ΔG) was calculated using the dimerization constant 
and Equation 3-3. We also calculated the effect of the mutations on dimer stability 
(ΔΔG), given by the difference in dimer stability between a given mutant and the wild-
type. From the optimal Intrinsic FRET values, we calculated the distance between the 
fluorescent proteins in each of the different FGFR3 dimers using Equation 3-8. 
 The dimeric fractions are shown in Figure 3-5, along with the binding curves 
corresponding to the optimal K values. The data are shown as averages within bins of 
5x104 receptors/nm2. A reduced χ2 analysis demonstrated that the small differences 
between the wild-type and the mutants are statistically significant. The reduced χ2 values 
are 36.03, 7.51, and 8.35, such that the p-values are all <0.001.  Further statistical 
analysis, however, shows that the effects are very modest, with the p-values from t-tests 
being 0.001, 0.15 and 0.006 for the Arg248Cys, Ser249Cys, and Tyr373Cys mutants, 
respectively. By ANOVA, only the effect of the Arg248Cys mutation is highly 
statistically significant. Statistical analysis of the values of Ẽ yields p-values of <0.001, 
<0.001, and 0.03 for the Arg248Cys, Ser249Cys, and Tyr373Cys mutants, respectively. 
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By ANOVA, the effects of the Arg248Cys and Ser249Cys mutations on Intrinsic FRET, 
and thus dimer conformation, are highly statistically significant. 
Discussion 
 In FRET studies of RTK dimerization, the measured FRET efficiencies depend on 
both RTK dimerization propensity and RTK dimer structure (particularly on the distances 
between the fluorescent proteins in the dimer). Unfortunately, this fact is sometimes not 
fully appreciated in FRET data interpretation.  In addition, the read-out of other 
experimental techniques used in RTK research also depends on both the dimerization 
propensity and on structural factors. For instance, receptor phosphorylation, measured in 
Western blot experiments using anti-phospho-tyrosine antibodies, requires that the 
receptors are dimeric but also depends on the exact positioning and orientation of the 
kinase domains. The TDI mutations have been shown to increase FGFR3 
phosphorylation (64), as compared with wild-type, but it is not known if the effect is due 
to increased dimerization or structural perturbations that promote phosphorylation. 
Similarly, cross-linking efficiencies, measured in Western blots using anti-receptor 
antibodies, depend both on the fraction of dimeric receptors and on the presence of 
suitable amine groups that are in close enough proximity for cross-linking to occur. Thus, 
a change in cross-linking due to a mutation may be due to either a change in dimerization 
propensity or a change in structure, or both.  
 In this study, we characterized the ligand-independent dimerization of three 
FGFR3 mutants linked to TDI in plasma membrane-derived vesicles using a FRET-based 
method. We overcome the limitations in data interpretation by separating structural 
effects from dimerization effects. This is accomplished by fitting a dimer model with two 
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adjustable parameters, the dimerization constant, K, and the structural parameter Intrinsic 
FRET, Ẽ, to the experimental data. 
Modest changes in dimer stability due to the TDI mutations in the absence of ligand 
 Dimerization constants report on the propensity for dimer formation. For the wild-
type receptor, we measured a dimerization free energy of ΔG = -3.4 ± 0.1 kcal/mol, 
which is consistent with previous FGFR3 experiments (26,43). Concurrent experiments 
on the Arg248Cys, Ser249Cys, and Tyr373Cys mutant constructs produced ΔG values of 
-4.2 ± 0.1, -3.7 ± 0.1, and -3.8 ± 0.1 kcal/mol, respectively.  Thus, the mutations have a 
very modest effect on dimer stability, confirmed by statistical analysis. 
Literature values for the energetic contributions of disulfide bonds to protein 
interactions vary substantially, with the most consensus values lying around 2-4 kcal/mol 
(84,85). Here, we measured that the Arg248Cys, Ser249Cys, and Tyr373Cys mutations 
stabilize the FGFR3 dimer by -0.8, -0.3, and -0.4 kcal/mol, respectively. These findings 
may suggest that disulfide bonds form with low probability within the unliganded TDI 
dimers, most likely due to structural constraints that make it difficult for disulfide bonds 
to form. This means that, in our experiments, we might probe two different mutant 
populations—one consisting of a disulfide bonded dimer structure and one consisting of a 
mutant dimer with a structure that is practically the same as the wild-type—and that our 
measurements of K and Ẽ are average values, not molecular characteristics of the 
disulfide bonded mutant dimers.  
Modest structural effects due to the TDI mutations in the absence of ligand 
 Intrinsic FRET values report on the distances between the fluorescent proteins in 
the dimer, and are influenced by the mobility of the fluorescent proteins. We show that 
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the Arg248Cys and Ser249Cys TDI mutations cause statistically significant effects on the 
Intrinsic FRET, implying that there are differences in the structures of the wild-type and 
mutant dimers.  Assuming free rotation of the fluorescent proteins, we calculate the 
average distance between the fluorescent proteins in the wild-type dimer as 53 ± 1 Å, 
compared with 45 ± 1 Å, 45 ± 1 Å, and 49 ± 1 Å for the Arg248Cys, Ser249Cys, and 
Tyr373Cys mutants, respectively. Therefore, the fluorescent proteins are likely closer to 
each other in the mutant dimers, suggesting a likely decrease in the separation between 
the TM domains.  
Implications 
 Disulfide bonds in proteins or protein complexes are always envisioned as very 
strong, due to their covalent nature. Thus, one expects that disulfide bonds strongly 
stabilize protein folds and protein assemblies. In accordance with this view, it is believed 
that the effects of pathogenic cysteine mutations in RTKs are profound, with the disulfide 
bonds inducing constitutive dimerization. Yet, actual experimental measurements of 
disulfide bond-mediated stabilization for soluble proteins and dimers point to rather 
modest effects, on the order of -2 to -4 kcal/mol (84,85). In this study, we present, to our 
knowledge, the first quantitative measurement of the effect of cysteine mutations on 
membrane protein interactions. In particular, we study the TDI mutations in FGFR3, 
which are linked to a lethal phenotype and are thus expected to induce constitutive 
FGFR3 dimerization. Surprisingly, we see very modest effects on FGFR3 dimerization. 
Furthermore, we see indications of structural perturbations in the FGFR3 dimer due to the 
mutations.  Thus, this study does not support the simple view that the TDI cysteine 
mutations cause pathologies by inducing constitutive FGFR3 dimerization.  
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Figure 3-2. FRET efficiency versus acceptor concentration for wild-type FGFR3 and the 
TD mutants. 
Wild-type FGFR3, FGFR3_R248C, FGFR3_S249C, and FGFR3_Y373C are shown with 
open blue diamonds, filled red squares, filled green triangles, and filled purple circles, 
respectively. Each data point represents a single vesicle and has a distinct donor 
concentration. The solid black line indicates the proximity FRET, known to occur due to 
random approach of donors and acceptors within distances of 100 Å in the membrane. 
The FRET data lie above this proximity line, indicating specific FGFR3 interactions. The 
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the wild-type receptors, indicating that the TDI mutations have an effect on FGFR3 
dimerization.  
  














Figure 3-3. Donor concentration versus acceptor concentration for WT FGFR3 and the 
TD mutants. 
Wild-type FGFR3, FGFR3_R248C, FGFR3_S249C, and Y373C are shown with open 
blue diamonds, filled red squares, filled green triangles, and filled purple circles, 
respectively. The wide spread of donor to acceptor concentrations explains the apparent 
wide spread of FRET efficiency observed in Figure 3-2. 
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Figure 3-4. Dimeric fraction times Intrinsic FRET, versus total receptor concentration for 
WT FGFR3 and the TD mutants. 
These data are obtained from the FRET data in Figure 3-2 using Equation 3-9, and are 
averaged within 5x10-4 receptors/nm2 wide concentration bins. A reduced χ2 analysis 
demonstrates that the mutant data sets are significantly different from the wild-type data 
set. 
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Figure 3-5. Dimeric fraction versus receptor concentration for WT FGFR3 and the TD 
mutants. 
Averaged data are shown in 5x10-4 receptors/nm2 wide bins. The solid line is the best fit 
to the homodimerization model, given by Equations 3-1 and 3-6, plotted for the 
optimized parameters in Table 3-1. A reduced χ2 analysis demonstrates that the 
differences between the mutant and wild-type dimeric fractions are statistically 
significant. 
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  Wild-type FGFR3_R248C FGFR3_S249C FGFR3_Y373C 
K 290 ± 60 1110 ± 130 500 ± 100 590 ± 110 
Ẽ 0.51 ± 0.04 0.74 ± 0.03 0.73 ± 0.03 0.62 ± 0.03 
ΔG (kcal/mol) -3.4 ± 0.1 -4.2 ± 0.1 -3.7 ± 0.1 -3.8 ± 0.1 
ΔΔG (kcal/mol)   -0.8 ± 0.1 -0.3 ± 0.1 -0.4 ± 0.1 
d (Å) 53 ± 1 45 ± 1 45 ± 1 49 ± 1 
 
Table 3-1. Optimal parameters describing homodimerization of WT FGFR3 and the TD 
mutants. 
The values of K and Ẽ are optimized in a two parameter fit of the homodimerization 
model to FRET data. Dimer stability, ΔG, is calculated according to Equation 3-3. The 
effect of the mutations on dimer stability, ΔΔG, is the difference between the wild-type 
and mutant dimer stabilities. The distance between fluorescent proteins, d, is calculated 
from Ẽ according to Equation 3-8.  
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CHAPTER FOUR Conformational Changes in FGFR1 and FGFR2 Homodimers in 
Response to the fgf Ligands that Regulate Embryonic Limb Development 
Receptor-Ligand Interactions and Embryonic Limb Development 
 Activation of membrane-bound receptors through ligand binding is a common 
motif in cell signaling pathways (4,10-13,86,87). Despite the recurrence of this activation 
mechanism, exactly how a receptor is able to discriminate between its many ligands, and 
to produce differential signaling outcomes, remains an open question (14,22,71,86,88-
90). Variations in receptor-ligand binding constants and spatiotemporal expression of 
both receptors and ligands provide some insight into this question (22,71,91), but fall 
short of a full explanation. Confounding factors include uniformity in the downstream 
signaling pathway of an activated receptor and co-expression of ligands (14,88,89). 
Conventional wisdom points toward the hypothesis that there are additional, unexplored 
mechanisms whereby receptors distinguish between their ligands. 
 The process of embryonic limb development is commonly employed as a model 
system in which to probe receptor-ligand interactions (89). This process is initiated when 
mesenchymal tissue accumulates under the ectoderm to form the limb bud. Signals from 
the mesenchyme induce formation of the apical ectodermal ridge (AER) from the 
ectodermal tissue. Subsequently, full limb development is regulated by both the 
mesenchyme and the AER. All steps in this process are primarily regulated through the 
FGFR subfamily of RTKs (22,88-94). FGFR1 is expressed exclusively in the 
mesenchyme, and FGFR2 is found only in the ectoderm/AER. The mesenchyme 
produces the fgf16 and fgf18 ligands, and the AER expresses the fgf4, fgf8, and fgf9 
ligands. Ligands produced in the AER preferentially bind receptors in the mesenchyme, 
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and vice versa (88,90,92-96). Deletion of each of these five ligands, or a combination 
thereof, yields unpredictable disruptions to limb development, which can range in 
severity from lethality to anatomical abnormalities to no observable effects (22,89,92,93). 
 The five fgf ligands implicated in embryonic limb development come from a 
family of 18 fgfs (13,14,71). The fgf ligands exhibit high sequence and structural 
homology, and activate FGFRs by binding the DII and DIII immunoglobin-like domains 
of the EC domain of a receptor. Only two of the four FGFRs are involved in embryonic 
limb development, though all four FGFRs display similarities in sequence and structure. 
FGFR1 and FGFR2 exhibit a particularly high homology, and have been shown to be 
functionally redundant in some cases. In the context of so much apparent similarity, the 
mechanism by which FGFR1 and FGFR2 are able to distinguish between the five fgf 
ligands and orchestrate the specific process of limb development remains unclear 
(14,22,88,89). 
 Previous work in the lab leveraged the QI-FRET technique to measure changes in 
the conformation of the FGFR1, FGFR2, and FGFR3 homodimers in response to the 
activating ligands fgf1 and fgf2 (18). In those experiments, the IC domain of each 
receptor was substituted with a fluorescent protein (eYFP or mCherry), to allow for 
FRET detection of homodimer formation. Samples were saturated with each ligand, to 
ensure that all receptors existed in the fully liganded homodimer state, and the Intrinsic 
FRET was measured for each receptor-ligand pair. Intrinsic FRET is the FRET efficiency 
in a given dimer. It is a conformational parameter that depends only on the separation of 
fluorophores in a dimer, and is independent of the propensity for dimer formation. For all 
three receptors, the measured Intrinsic FRET was smaller in the presence of fgf1 as 
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compared to fgf2. This work contributes to a growing body of evidence that homodimer 
conformation might contribute to the mechanism by which receptors distinguish between 
their various activating ligands (71,97).  
 Here, we consider the question of how receptors differentiate between their 
activating ligands in the context of embryonic limb development. Our selection of 
receptors and ligands is based on previous studies in chick embryos (89,95,96) and mice 
(22,88,89,91-93). Limited studies in humans (94) verify the assumption that the same 
receptors and ligands regulate development of human limbs. We work with human 
FGFR1c and FGFR2c, where the IC domain of each receptor has been replaced with a 
flexible linker followed by a fluorescent protein, and the human fgf4, fgf8, fgf9, fgf16, 
and fgf18 activating ligands. We use the QI-FRET method to measure the Intrinsic FRET 
for each of the ten possible receptor-ligand pairs. We examine our results for clues as to 
how each FGFR differentiates between the five activating ligands present in embryonic 
limb development. 
Fully Liganded Homodimer Model 
 In these experiments, we consider a special case of the homodimerization model 
presented in Chapter Three. Receptors are saturated with ligand, which shifts the 
equilibrium of Equation 3-1 such that all receptors exist as homodimers. That is, the 
association constant, K, is infinite, and the concentration of monomers, [M], is equal to 
zero. Experiments are performed in vesicles, so receptor concentration is constant 
(Equation 3-4), and dimer fraction, given by Equation 3-5, is equal to one. 
Interpretation of Fully Liganded Homodimer FRET Data 
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 Homodimer FRET data is interpreted as presented in Chapter Three. The 
measured FRET efficiency is corrected for the proximity FRET (77,82), to yield the 
dimer-specific FRET efficiency, ED. In typical homodimer FRET experiments, we 
consider the quantity dimeric fraction times Intrinsic FRET, as given in Equation 3-9. In 
the case of fully liganded homodimers, fD is equal to one, so Equation 3-9 reduces to: 
      
  
  (4-1) 
where Ẽ is the only unknown. We use Equation 4-1 to directly calculate the Intrinsic 
FRET in each vesicle.  
 Intrinsic FRET, or Ẽ, is the FRET efficiency in a given dimer, which depends on 
the separation and orientation of the two fluorophores. The fluorescent proteins are 
attached to the TM domain of the receptors via flexible (GGS)5 linkers, which allows the 
fluorophores to rotate freely. Under this assumption of free fluorophore rotation, we use 
Equation 3-8 to calculate the distance between fluorophores in a given homodimer. 
Figure 4-1 is a cartoon representation of Intrinsic FRET, which helps demonstrate how 
the binding of different ligands might relate to changes in homodimer conformation. 
Here, we measure Intrinsic FRET values for fully liganded homodimers in order to 
compare homodimer conformations in response to various activating ligands. 
Statistical Analysis 
 For each of the receptor-ligand pairs considered here, we analyze a few hundred 
vesicles. First, we sort vesicles by their Intrinsic FRET values (bin size of 0.05) to 
generate a histogram. Then, we fit a Gaussian distribution to the histogram. The mean of 
this Gaussian is the Intrinsic FRET for a given fully liganded homodimer. To estimate the 
error of our measure for Intrinsic FRET, we employ the bootstrap method. In this 
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method, a dataset is split into multiple subsets, each of which are fit separately. Then, the 
results of the fit for each subset (in this case, the mean Intrinsic FRET) are used to 
calculate an average and a standard deviation  
 We perform one-way analysis of variance (ANOVA) tests to compare the 
Intrinsic FRET values measured for a given receptor in the presence of each of the five 
activating ligands. We test the null hypothesis that the Intrinsic FRET values for all five 
fully liganded homodimers are the same. If p < 0.05, we reject that hypothesis and 
perform a multiple comparison post-test to identify statistically significant differences 
among the Intrinsic FRET values for the fully liganded homdimers. 
Results  
 In these experiments, we examined the FGFR1 and FGFR2 homodimers in the 
presence of five different ligands: fgf4, fgf8, fgf9, fgf16, and fgf18. Both receptors and 
all five ligands have been shown to play critical roles in embryonic limb development. 
Each receptor-ligand pair has a unique function, but the molecular basis of how these 
receptor-ligand pairs vary, and thereby generate different outcomes, remains unclear. To 
begin to unravel the molecular differences between these receptor-ligand pairs, we 
measured the Intrinsic FRET, a parameter that reports on dimer conformation, for all ten 
receptor-ligand pairs. Specifically, we use Intrinsic FRET to assess and compare the 
homodimer conformation of each receptor in the presence of every ligand. 
 Experiments were performed with truncated receptors in cell-derived vesicles. We 
worked with plasmids coding for the EC and TM domains of the FGFR followed by a 
flexible linker and a fluorescent protein (eYFP or mCherry). The substitution of the IC 
domain with a fluorophore enables FRET detection of homodimer formation. The 
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plasmids were expressed in CHO cells, so that truncated receptors were trafficked to the 
membrane by the native cell machinery and underwent all relevant post-translation 
modifications. To obtain vesicles containing the fluorescently-labeled FGFR, these CHO 
cells were subjected to a gentle protocol that uses changes in osmotic pressure to induce 
vesicle production (43). The lipid and protein content of these vesicles is representative 
of the membranes of live cells (44). Vesicles were harvested and placed in a glass-
bottomed chamber slide for further analysis. 
 Ligand was added to each sample at a saturating concentration of 5 μg/mL. This 
high concentration of ligand was selected because it exceeds the receptor-ligand binding 
constant by multiple orders of magnitude (98-101), ensuring that all receptors will exist 
as homodimers (that is, the equilibrium of Equation 3-1 will be pushed entirely to the [D] 
state). Samples were incubated at room temperature for 1 hour following ligand addition, 
to allow for the ligand binding and homodimer formation processes to reach equilibrium. 
This time allocation far exceeds the literature estimates for the kinetics of both the fgf 
binding and FGFR dimerization reactions (98,101). Vesicles were imaged according to 
the QI-FRET protocol, which yields the acceptor concentration, donor concentration, and 
FRET efficiency in each vesicle. We prepared a minimum of three samples and imaged 
between 200 and 500 vesicles for each of the ten possible receptor-ligand pairs  
FGFR1 and FGFR2 form fully liganded homodimers in the presence of fgf4, fgf8, fgf9, 
fgf16, and fgf18 
 Here, we consider the FGFR1 and FGFR2 homodimers in the presence of the five 
ligands―fgf4, fgf8, fgf9, fgf16, and fgf18―that regulate embryonic limb development. 
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QI-FRET results for FGFR1 and FGFR2 are displayed in Figure 4-2 and Figure 4-3, 
respectively, with panels A through E corresponding to fgf4, fgf8, fgf9, fgf16, and fgf18.  
 The panel for each receptor-ligand pair consists of four plots. In the top half of the 
panel, we display raw data from QI-FRET experiments. In the upper left-hand corner, we 
plot measured FRET efficiency as a function of acceptor concentration. Each point 
represents a single vesicle. The solid black line indicates the proximity FRET, or the 
FRET efficiency that arises due to random close approach of receptors in the two-
dimensional membrane. For each of the receptor-ligand pairs examined, the measured 
FRET efficiencies exceed proximity FRET, suggesting specific receptor-receptor 
interactions in the presence of ligand. In the upper right-hand corner, we plot donor 
concentration versus acceptor concentration. Both concentrations affect measured FRET 
efficiency and are accounted for when calculating the Intrinsic FRET in each vesicle. 
 Next, measured FRET efficiencies are corrected for proximity FRET as described 
previously (77), yielding the dimer-specific FRET efficiencies, ED. In the lower left-hand 
corner, we plot ED as a function of total receptor concentration. For all of the receptor-
ligand pairs studied here, dimer-specific FRET efficiency is constant as a function of 
receptor concentration, indicating that all receptors exist as fully liganded homodimers. 
This observation verifies the assumption that the saturating ligand conditions shift the 
equilibrium of Equation 3-1 entirely to the dimer state. 
 Finally, the Intrinsic FRET is calculated for each vesicle according to Equation 
4-1. These results are binned to generate a histogram, which is displayed in the lower 
right-hand corner. The blue bars represent binned experimental data, and the solid red 
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line is the best fit Gaussian distribution. The mean of this Gaussian distribution is the 
Intrinsic FRET for the receptor-ligand pair being considered.  
 For the FGFR1 homodimer bound to the activating ligands fgf4, fgf8, fgf9, fgf16, 
and fgf18, we measure Intrinsic FRET as 0.506 ± 0.001, 0.417 ± 0.009, 0.494 ± 0.010, 
0.432 ± 0.010, and 0.510 ± 0.002, respectively. The analogous values for the FGFR2 
homodimer are 0.644 ± 0.009, 0.580 ± 0.007, 0.651 ± 0.010, 0.632 ± 0.004, and 0.646 ± 
0.004. Equation 3-8 relates Intrinsic FRET to the distance, d, between fluorophores in a 
homodimer. We use that relation to estimate the inter-fluorophore distance in each fully 
liganded homomdimer. The Intrinsic FRET and inter-fluorophore distance for all ten 
receptor-ligand pairs examined here are tabulated in Table 4-1. 
Conformational changes in the FGFR1 and FGFR2 homodimers in the presence of some 
ligands 
 We perform an ANOVA test to compare the Intrinsic FRET values for the FGFR1 
homodimer in the presence of each of the five activating ligands. The p-value for the 
initial ANOVA test is 4.5x10-8, so we reject the null hypothesis that the Intrinsic FRET 
for all five liganded FGFR1 homodimers is the same. The multiple comparison post-test 
indicates that the FGFR1 homodimer conformations in the presence of fgf8 and fgf16 are 
statistically the same as each other and different from the homodimer conformations in 
the presence of fgf4, fgf9, and fgf18, which form a second statistical group. 
 We follow the same protocol to compare Intrinsic FRET values for the FGFR2 
homodimer. We reject the null hypothesis that the five FGFR2 homodimer conformations 
are the same (p = 1.8x10-6). The post-test reveals that Intrinsic FRET for the liganded 
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FGFR2 homodimers in the presence of fgf4, fgf9, fgf16, and fgf18 are statistically the 
same as each other, and different from the Intrinsic FRET in the presence of fgf8. 
 The FGFR1 and FGFR2 Intrinsic FRET values and results of both ANOVA tests 
are displayed in Figure 4-4. 
Discussion 
 In these experiments, we measure changes in the conformation of the FGFR1 and 
FGFR2 homodimer, seen through changes in Intrinsic FRET, in response to five 
activating ligands (see Figure 4-4). This result is another piece of evidence in support of 
the hypothesis that homodimer conformation is a key component of how a receptor 
distinguishes between ligands (71,97). However, our results do not provide much insight 
into the mechanistic underpinnings of receptor-ligand interactions in embryonic limb 
development. Differences in measured Intrinsic FRET do not depend on the tissue of 
ligand origin. Furthermore, they are small as compared to those measured for FGFR1, 2, 
and 3 in response to fgf1 and 2 (18), and do not follow any other obvious trend, including 
magnitude of the receptor-ligand binding constant (99,101). 
 It is worth noting the possibility that receptor-ligand pairs with the same Intrinsic 
FRET might have very different homodimer conformations. As diagrammed in Figure 
4-1, Intrinsic FRET reports on changes in homodimer conformation through the 
separation of fluorophores. Since fluorescent proteins are attached to the TM domain of 
each receptor by flexible linkers, Intrinsic FRET is believed to be most sensitive to 
changes in the separation of the C-termini of the TM domains. TM domain conformation 
depends on both helix separation and rotation, both of which have been shown to 
influence signaling (27,102). Intrinsic FRET cannot capture rotational changes in TM 
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helix orientation or overall homodimer conformation, which may explain why so many of 
the receptor-ligand pairs studied here are indistinguishable from each other. 
 Additional experiments should be performed to address the questions left 
unanswered by this work. First, the possibility of multiple homodimer conformations 
should be more completely explored. RTKs are hypothesized to have multiple 
dimerization interfaces. This idea is supported by work with a diverse array of 
techniques, including traditional biochemistry (102), fluorescence (30,103), nuclear 
magnetic resonance spectroscopy (27), and molecular dynamics simulations (104) . These 
types of experiments should be replicated, in order to identify the possible dimerization 
interfaces of FGFR1 and FGFR2. Mutagenesis and additional QI-FRET experiments can 
confirm the functional in/significance of these interfaces and may allow for direct 
correlation between Intrinsic FRET and homodimer conformation for each receptor-
ligand pair.  
 A second set of experiments should focus on tying the physical models of 
receptor activation generated by QI-FRET experiments to biological outcomes. In 
previous work, phosphorylation of FGFR3 was shown to scale linearly with Intrinsic 
FRET (18). Thus, Western blots should be performed, in order to assess the 
phosphorylation of both FGFR1 and FGFR2 in response to the five activating ligands. 
 Together, QI-FRET experiments, investigation of dimerization interfaces, and 
Western blots may produce further insight into the molecular mechanism by which 
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concentration. Finally, we calculate the Intrinsic FRET in each vesicle (Equation 3-8) and 
bin these values to generate the histogram in the lower right-hand corner. The solid red 
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fgf4 0.506 ± 0.001 52.9 ± 0.1 
fgf8 0.417 ± 0.009 56.1 ± 0.7 
fgf9 0.494 ± 0.010 53.3 ± 0.7 
fgf16 0.432 ± 0.010 55.6 ± 0.7 




fgf4 0.644 ± 0.009 48.1 ± 0.6 
fgf8 0.580 ± 0.007 50.3 ± 0.5 
fgf9 0.651 ± 0.010 47.9 ± 0.7 
fgf16 0.632 ± 0.004 48.5 ± 0.3 
fgf18 0.646 ± 0.005 48.1 ± 0.4 
 
Table 4-1. FGFR1 and FGFR2 Intrinsic FRET and inter-fluorophore distance in the 
presence of five activating ligands. 
Intrinsic FRET for FGFR1 (top half of table) and FGFR2 (bottom half) in response to the 
five ligands that regulate embryonic limb development. Inter-fluorophore distance is 
calculated, under the assumption of free fluorophore rotation, using Equation 3-8. 
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CHAPTER FIVE A New Method to Study Heterodimerization of Membrane 
Proteins and its Application to Fibroblast Growth Factor Receptors 
This research was originally published in the Journal of Biological Chemistry. Nuala Del 
Piccolo, Sarvenaz Sarabipour, and Kalina Hristova. A New Method to Study 
Heterodimerization of Membrane Proteins and its Application to Fibroblast Growth 
Factor Receptors. Journal of Biological Chemistry. 2016; Papers in Press. © the 
American Society for Biochemistry and Molecular Biology. 
The text reproduced here has been revised to match the style of this thesis. 
RTK Heterodimerization and the FGFRs 
 Receptor tyrosine kinases (RTKs) regulate many key biological processes, 
including cell survival, growth, differentiation, and migration. There are 58 different 
RTKs, classified into 20 families based on sequence similarity. An archetypal RTK 
consists of a ligand-binding extracellular (EC) domain, a single-pass transmembrane 
(TM) domain, and an intracellular (IC) kinase domain (4,11,13,14,16). These receptors 
are activated upon dimerization, which is known to be a reversible process (105,106). 
Dimer formation is required (although not sufficient) for function (4,18,19,105,107,108), 
as it brings the two kinases into close proximity, enabling cross-phosphorylation on 
specific tyrosines. Phosphorylated RTKs trigger many intracellular signaling cascades, 
including the MAPK, PI3K, PKC, and STAT pathways. These pathways, in turn, 
determine cell fate and function (4,11,13,14,16,91,109). 
RTKs play a fundamental role in human development. They are also critical 
players in the induction and progression of many cancers (4,11,13-16,91,110). Thus, 
significant efforts have been dedicated to the development of RTK-specific therapies 
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with high specificity and low toxicity. One class of anti-cancer drugs on the market 
specifically aims to inhibit RTK dimerization, as it is an important regulator of function. 
The best known example of these drugs is Herceptin, an antibody raised against the 
extracellular domain of HER2, an RTK that is often overexpressed in breast cancer 
(15,111). While Herceptin treatment can significantly improve patient outcomes in some 
cases, the performance of this treatment and other RTK-targeted molecular therapies has 
not reached expectations (16,111,112). This may be partly due to gaps in basic 
knowledge about RTK interactions in the plasma membrane.  
RTKs readily form homodimers, but they also participate in hetero-interactions 
with other RTKs, often other members of the same family. Heterodimerization between 
RTKs is believed to be a means of signal amplification and diversification. RTK 
heterodimers have been shown to enhance receptor activation and downstream signaling, 
as compared to homodimers (4,11,15,16,30,113). For instance, the ErbB2•ErbB3 
heterodimer is known as the most biologically active and the most pro-tumorigenic of all 
ErbB homodimers and heterodimers (15,16). Yet, our understanding of RTK 
heterodimerization is only rudimentary, in part due to a paucity of methods that provide 
quantitative information about heterodimer formation (21,113,114). Indeed, prior work 
has relied primarily on qualitative methods such as immunoprecipitation. Thus, the extent 
of heterodimerization between members of an RTK family remains unknown. Often, 
even the identities of RTK partners that engage in hetero-interactions are unknown, and 
this can significantly impede the design of high efficacy therapeutics that target RTK 
dimerization. 
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Here, we introduce a novel Förster Resonance Energy Transfer (FRET)-based 
technique that overcomes the limitations of previous methods employed to study 
heterodimers in the plasma membrane. To demonstrate the utility of the method, we 
apply it to study heterodimerization within the Fibroblast Growth Factor Receptor 
(FGFR) family of RTKs. We use truncated receptors in which the IC domains have been 
substituted with fluorescent proteins, to allow for FRET detection. Measurements are 
performed in plasma membrane vesicles, derived from live cells using an osmotic stress 
buffer (43). As the receptors are expressed in cells prior to vesicle production, they 
undergo all post-translational modifications. FRET is measured with the Quantitative 
Imaging-FRET (QI-FRET) method (54,55), which yields donor and acceptor 
concentrations, in addition to FRET efficiencies, in each vesicle.  
  The FGFRs regulate the development of the skeletal system 
(13,23,91,109,115,116). There are four FGFRs—FGFR1, FGFR2, FGFR3, and FGFR4. 
Here we focus on FGFR1, FGFR2, and FGFR3, three receptors that have been implicated 
in many growth disorders (4,11,13,14,18,69,91,116,117). While originally believed to 
form dimers only in response to ligand (fgf) binding, FGFRs have been shown to interact 
and form homodimers even in the absence of ligand (18,26,34,118-120). FGFR 
homodimerization seems to prime the receptors for efficient activation by the ligand, and 
thus unliganded FGFR dimers appear to be important intermediates in the signal 
transduction process (18,120). 
The propensities for homodimer formation have been quantified for full-length 
FGFR1, FGFR2, and FGFR3, in the absence of ligand (18). The truncated FGFRs also 
form homodimers, with propensities that are similar to or lower than full-length FGFRs 
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(18,34,118,119). We seek to determine the heterodimerization propensities of the 
truncated FGFR1, FGFR2, and FGFR3, and compare them to the homodimerization 
propensities, in the absence of ligand.  
We further seek to examine FGFR heterodimer formation in the presence of two 
different pathogenic point mutations in FGFR3: G380R and A391E. The G380R 
mutation in the TM domain of FGFR3 is found in 98% of all Achondroplasia cases. 
Achondroplasia is the most common form of human dwarfism and is characterized by 
short stature and premature endochondral ossification of long bones 
(21,23,67,69,109,115,116,119). The A391E mutation, also in the TM domain of FGFR3, 
causes Crouzon syndrome with acanthosis nigricans. This developmental disorder is 
characterized by premature ossification of skull bones accompanied by a skin disorder 
(24,94,116,118,121,122). While both mutations introduce a charged amino acid into the 
TM domain of the same receptor, the resulting phenotypes are substantially different. It 
has been hypothesized that this difference in phenotype might be explained by disparate 
perturbations to FGFR heterodimers (24,116). To directly test this hypothesis, we 
examine the FGFR1•FGFR3, FGFR2•FGFR3, and wild-type\mutant FGFR3 
heterodimers in the presence of both mutations using the new quantitative FRET method, 
and we compare the results to those of the wild-type using statistical methods. 
Heterodimerization Model 
 RTK lateral association can be described by monomer-dimer equilibrium models 
(11,114,123). Here, we consider dimer formation when two receptors, X and Y, are 
capable of forming both heterodimers and homodimers (see Figure 5-1). In this case, the 
equilibrium between monomers and dimers is described by three reactions (124): 
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        (5-1) 
where KX and KY are the two macroscopic homodimer association constants and KXY is 
the macroscopic heterodimer association constant. The bracket notation indicates two-
dimensional species concentration. The three association constants can be written as: 
    
    
    
    
    
    
     
    
      
 (5-2) 
and these relationships are the first key component describing the complex 
heterodimerization process. The association constants can be used to calculate dimer 
stability using Equation 3-3. The number of receptors in a cell-derived vesicle is constant 
over time, and we write the equations of mass conservation as: 
                                                 (5-3) 
where [Xtotal] and [Ytotal] are the total concentrations of each receptor species in a given 
vesicle. If we rearrange the first two statements in Equation 5-2 to solve for [XX] and 
[YY] and substitute into Equation 5-3, we have: 
                                                     (5-4) 
These equations constitute the second key component describing heterodimerization. 
Using the quadratic formula (125) to solve Equations 5-4 for [X] and [Y], and then 
substituting into the third statement in Equation 5-2, we arrive at a single equation 
describing heterodimerization: 
       
                
                       
  
                
                       
       (5-5). 
This equation is implicit and must be solve numerically. To achieve this, we can employ 
MATLAB's function "fsolve" in the default setting, which utilizes the trust-region-dogleg 
algorithm. Solving Equation 5-5 in this manner produces theoretical predictions for the 
 66   
 
concentration of heterodimers, which depend on the homodimer association constants, 
KX and KY, and on the total receptor concentrations, [Xtotal] and [Ytotal]. The total dimer 
fraction, fD, is: 
    
                 
                 
 (5-6). 
This value is also equivalent to the sum of the two homodimer fractions, fD,XX and fD,YY, 
and the heterodimer fraction, fD,XY: 
      
     
                 
       
     
                 
      
     
                 
 (5-7). 
Interpretation of Heterodimer FRET Data 
 Next, we turn to solving the heterodimerization problem in the context of FRET 
experiments. If the two receptors form heterodimers, and if one receptor is labeled with 
the donor and the other is labeled with the acceptor, FRET will occur. The FRET 
efficiency can be measured with the QI-FRET method as described (54,55). The 
measured FRET efficiency can then be corrected for the so-called proximity FRET, to 
yield the interaction-specific FRET efficiency, ED. Proximity FRET is a non-negligible 
FRET efficiency that arises even in the absence of specific interactions, due to the 
random approach of donors and acceptors within the two-dimensional membrane. We 
have extensively modeled and measured this phenomenon in previous work, and it 
mainly depends on acceptor concentration (77,82). The corrected FRET efficiency, ED, is 
due to heterodimerization only. FRET efficiency is based on the change in donor 
fluorescence, so ED can be written in terms of the concentration of the acceptor-donor 
complex (that is, the heterodimer) and the concentration of the donor (121,126,127): 
    
      
       
 (5-8) 
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where Ẽ is the Intrinsic FRET, or the FRET efficiency in a given dimer. Intrinsic FRET is 
the maximum ED; that is, if all receptors in a vesicle were found in heterodimers, ED 
would be equal to Ẽ. In the general case, Ẽ depends on the relative positioning of the two 
fluorescent proteins (i.e. the separation and orientation of the fluorophores) in the dimer. 
Since the fluorophores are attached to the receptors via long flexible linkers, we can 
assume that they rotate freely, and thus Intrinsic FRET depends mainly on fluorescent 
protein separation. Under the assumption of free rotation, Intrinsic FRET can be written 
using Equation 3-8. Given an Intrinsic FRET value, Equation 3-8 can be solved for d to 
estimate fluorophore separation in a given dimer. 
 Using QI-FRET, we can measure three values per vesicle: donor concentration, 
acceptor concentration, and FRET efficiency (54,55). Since one receptor is labeled with 
the donor and the other receptor is labeled with the acceptor, the receptor concentrations, 
[Xtotal] and [Ytotal], can be directly measured as the donor concentration and acceptor 
concentration. To calculate heterodimer concentration from experimental data, we 
rearrange Equation 5-8 to obtain: 
               
  
 (5-9) 
and this relationship is substitute into Equation 5-5 to yield: 
      
  
         
  
          
         
         
  
          
  
  
         
  
          
         
         
  
          
  
         
  
  (5-10). 
The quantities [Xtotal], [Ytotal], ED, and [donor] are measured experimentally. When KX 
and KY are known, Equation 5-10 can be fit to experimental FRET data to find the 
unknowns KXY and Ẽ, the two parameters describing heterodimer formation. 
Statistical Analysis 
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A two-step process is used to fit the heterodimerization model to the experimental 
FRET data, ultimately identifying the optimal values for the unknowns KXY and Ẽ. First, 
Ẽ is fixed and non-linear least squares (128) (specifically, MATLAB’s “nlinfit”) is used 
to find KXY. This process is repeated at discreet values of Ẽ with a step of 0.01. Second, 
the mean square error (MSE) is calculated (128) for each of the resulting (Ẽ, KXY) pairs 
as: 
     
                      
  
   
 
 (5-11) 
where ED is the interaction-specific FRET efficiency. The experimental value,          , is 
measured in each vesicle using the QI-FRET method (54,55). The theoretical value, 
         , is calculated by solving Equation 5-5 for [XY] using the receptor concentrations 
in a given vesicle, then substituting into Equation 5-9 and solving for ED. n is the total 
number of vesicles in a given dataset. The lowest MSE corresponds to the optimal 
parameters. A plot of the MSE as a function of Ẽ is U-shaped. The minimum MSE was 
identified (using MATLAB's "min") and the (Ẽ, KXY) pair corresponding to this 
minimum is taken as the optimal set of parameters. 
 We note that we use this two-step process because MATLAB's nlinfit could not 
fit for both parameters simultaneously, as one of the parameters was consistently 
imaginary.  To confirm that this issue arises from the equations and not the data, we 
generated simulated heterodimer datasets where we fixed KXY and Ẽ and then attempted 
to use nlinfit to retrieve both parameters simultaneously. Despite the fact that this data is 
error-free and fits the model perfectly, nlinfit continued to produce imaginary parameter 
values. Employing the iterative approach, on the other hand, allowed us to successfully 
retrieve both parameters.  
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 Next, we use the bootstrap method (125) to estimate the errors on these 
parameters. In the bootstrap method, a given set of data is split into multiple synthetic 
datasets and the fitting process is performed on each subset. The optimal parameters from 
the subsets are used to calculate parameter means and standard deviations.  
 One-way analysis of variance (ANOVA) tests are performed to compare the 
association constants and Intrinsic FRET values for wild-type homodimers and 
heterodimers. First, the bootstrap method is used to refit the previously published 
homodimer data (18,34), in order to make the homodimer and heterodimer datasets 
comparable. Then, the optimal parameters from these fits are compared to K and Ẽ for 
the wild-type heterodimers using one-way ANOVA tests (MATLAB's “anova1”). We 
test the null hypothesis that the three homodimers and three heterodimers are all 
equivalent. In the case of p < 0.05, we reject the null hypothesis and perform a multiple 
comparison test (MATLAB's function “multcompare”) to determine which homodimers 
and/or heterodimers are significantly different from the others. 
Finally, KXY and Ẽ are compared using unpaired t-tests (MATLAB’s “ttest2”), in 
order to determine the effect of the two pathogenic point mutations. Each mutant 
heterodimer is compared to the corresponding wild-type heterodimer, and the wild-
type\mutant FGFR3 heterodimers are each compared to the wild-type FGFR3 
homodimer. We test the null hypothesis that the two dimers being compared are not 
significantly different from each other. The resulting p-values are recorded, where p < 
0.05 indicates that the two groups are significantly different, and p < 0.005 indicates a 
very significant difference. 
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Results 
Predictions of the model 
Equation 5-5 predicts the heterodimer concentration [XY], based on each 
receptor’s concentration and the two homodimer association constants. Solving Equation 
5-5 can be a challenging problem. In previous work (30,121,129,130), the ratio of 
receptor concentrations, [Xtotal]:[Ytotal], was held constant so that all equations can be 
written as a function of just one receptor concentration, substantially simplifying the 
mathematical analysis. However, our experiments are performed in a cellular system, 
which means that the concentration of each receptor, and thus the ratio [Xtotal]:[Ytotal], 
cannot be controlled. Instead, we must consider and solve Equation 5-5 as a function of 
both [Xtotal] and [Ytotal].  In this general case, the theoretical solution is a surface instead 
of a line. Additionally, since heterodimerization is described by a coupled system of 
equations, the formation of any dimer species—[XX], [YY], or [XY]—is dependent on 
the formation propensity of the other two.  
Figure 5-2 illustrates both of these characteristics using a series of graphs 
generated over a wide range of possible individual receptor concentrations.  In these 
predictions, the homodimer association constants KX and KY are varied by an order of 
magnitude, while keeping KXY fixed in all cases. In the left-hand panels, the theoretical 
total dimer fraction, fD, is represented by a cyan surface with contour lines. The total 
dimer fraction plots can be asymmetrical depending on the relative values of the 
homodimer association constants.  The right-hand panels depict the contribution of each 
dimer species to the total dimer fraction, where the fractional contribution of [XX], [YY], 
and [XY] are displayed as violet, pink, and white surfaces, respectively. The features of 
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these theoretical solutions are in accordance with the law of mass action. Homodimer 
fraction is low when the concentration of a given receptor is low and increases with its 
concentration, and heterodimer fraction approaches zero as either [Xtotal] or [Ytotal] (or 
both) go to zero. Note that the heterodimerization fraction decreases from panel A to 
panel D, despite the fact that KXY is the same in all cases. This decrease is due to the 
relative increases in KX and KY, i.e, due to the depletion of monomers as 
homodimerization increases. These predictions illustrate the complex manner in which 
receptor concentrations and association constants determine each dimer’s concentration. 
FGFR1, FGFR2, FGFR3, FGFR3_G380R, and FGFR3_A391E form all possible 
heterodimers 
We use the model described above to study the heterodimerization of truncated 
FGFRs, consisting of the EC and TM domains of a receptor followed by flexible linkers 
and fluorescent proteins. First, we consider the hetero-interactions between wild-type 
FGFR1, FGFR2, and FGFR3. Then, we examine these hetero-interactions when FGFR3 
carries the point mutations for Achondroplasia (FGFR3_G380R) or Crouzon syndrome 
with acanthosis nigricans (FGFR3_A391E). We investigate three possible wild-type 
FGFR heterodimers: FGFR1•FGFR2, FGFR1•FGFR3, and FGFR2•FGFR3; and six 
possible mutant heterodimers: FGFR1•FGFR3_G380R, FGFR2•FGFR3_G380R, 
FGFR3•FGFR3_G380R, FGFR1•FGFR3_A391E, FGFR2•FGFR3_A391E, and 
FGFR3•FGFR3_A391E.  
For each heterodimer studied, Chinese Hamster Ovary (CHO) cells are co-
transfected with plasmids encoding the two receptor constructs, each labeled with either 
the donor or the acceptor (and then the labeling scheme is reversed). Twenty-four hours 
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post-transfection, cells are exposed to an osmotic stress buffer (43) that produces plasma 
membrane-derived vesicles. These vesicles are collected and then imaged using the QI-
FRET method (54,55). In brief, a confocal microscope is used to image the cross-section 
of each vesicle in the donor, FRET, and acceptor channels (see Figure 2-3 for a 
representative vesicle). The microscope is calibrated using solutions of free fluorescent 
protein, so that fluorescence intensity and protein concentration can be directly related, 
enabling quantitative analysis of images (53). Ultimately, three quantities are measured in 
each vesicle: donor concentration, acceptor concentration, and FRET efficiency. 
Figure 5-3 displays the raw data for the nine FGFR heterodimers examined here. 
The left-hand panels show the FRET efficiency as a function of acceptor concentration. 
The dark blue right-pointing triangles, purple up-pointing triangles, green left-pointing 
triangles, light blue diamonds, and black squares represent the FGFR1, FGFR2, FGFR3, 
FGFR3_G380R, and FGFR3_A391E homodimer FRET data, respectively (previously 
published (18,34,118,119)). In each case, the heterodimer data are represented by red 
circles. Each point corresponds to a single vesicle. The solid black line represents the 
proximity FRET, or the FRET efficiency expected due to non-specific close approach of 
labeled receptors (77,82). For all wild-type and mutant FGFR heterodimers, measured 
FRET efficiencies exceed proximity FRET, indicating that specific heterodimeric 
interactions occur in all cases.  
 While FRET is plotted in Figure 5-3 as a function of acceptor concentration, it 
also depends on the donor concentration, and thus both concentrations are taken into 
account in the analysis. The right-hand panels in Figure 5-3 plot the donor concentration 
versus the acceptor concentration for all vesicles analyzed in the heterodimer FRET 
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experiments, again using red circles. The substantial variation of the ratio between 
acceptors and donors occurs because, in a transient transfection experiment, every cell 
will produce a different amount of each receptor. This variation explains the seemingly 
wide spread of FRET efficiencies seen in the FRET efficiency versus acceptor 
concentration plots.  As discussed previously, a wide range of donor to acceptor ratios, as 
well as a wide range of concentrations, is an advantage in the QI-FRET methodology, as 
it ensures a robust fit of a dimerization model to FRET data (55). 
FGFR heterodimer stabilities and Intrinsic FRET values can be quantified 
We fit the heterodimerization model (Equation 5-10) to the experimental FRET 
measurements for each heterodimer pair. We have previously reported all relevant 
homodimer association constants (18,34,118,119). We list those values in Table 5-1 and 
we use them as KX and KY in Equation 5-10. This analysis yields the optimal KXY and Ẽ. 
The apparent association constant, KXY, reveals the propensity for heterodimer formation 
and is used to calculate dimer stability, ΔGXY (Equation 3-3). Intrinsic FRET, or Ẽ, is a 
structural parameter that depends on the positioning of the fluorescent proteins in the 
dimer, but not on the propensity for dimer formation. Note that both KXY and Ẽ determine 
the magnitude of the measured FRET efficiencies, and thus both parameters need to be 
determined and accounted for, in order to correctly interpret results. In Table 5-1, we 
report the optimal KXY and Ẽ parameters, along with the calculated dimer stabilities and 
estimated distances between fluorescent proteins for all nine heterodimers. 
In Figure 5-4 and Figure 5-5, we compare experimentally determined values to 
the optimized heterodimer model for each heterodimer pair. In Figure 5-4, the 
heterodimer concentration [XY] is plotted as a function of both receptor concentrations, 
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with model values (Equation 5-5) and experimentally determined measurements 
(Equation 5-9) shown as a yellow surface with contour lines and open blue (above 
surface) and red (below) circles, respectively. In Figure 5-5, the total dimer fraction, 
calculated using Equation 5-6, is plotted as a function of the concentration of the two 
receptors. Model values are displayed as a cyan surface with contour lines, and 
experimentally determined measurements are plotted using purple circles. 
The wild-type FGFR1•FGFR2, FGFR1•FGFR3, and FGFR2•FGFR3 heterodimer 
stabilities are -4.5 ± 0.1, -4.8 ± 0.1, and -4.1 ± 0.2 kcal/mol, respectively (Table 5-1 and 
Figure 5-6). ANOVA tests are performed to compare ∆G values of homodimers and 
heterodimers. The stabilities of the FGFR2 and FGFR3 homodimers are statistically the 
same as each other, but different from those of FGFR1 and all the heterodimers. 
Additionally, the stabilities of FGFR1•FGFR2 and FGFR1•FGFR3 are statistically the 
same as each other, but different from the stability of FGFR2•FGFR3. The ΔG for 
FGFR1•FGFR3 is also different from that of FGFR1.  
We also use ANOVA to compare wild-type Intrinsic FRET values. We find that 
Intrinsic FRET is statistically the same for all three wild- type homodimers and the 
FGFR1•FGFR2 and FGFR2•FGFR3 heterodimers. The Intrinsic FRET of the 
FGFR1•FGFR3 heterodimer is smaller than that of the other five dimers, and this 
difference is significant. In our experiments, the fluorescent proteins are attached to the 
TM domain of each FGFR via flexible linkers, so Intrinsic FRET predominantly depends 
on the distance between the fluorescent proteins in the dimers, d. Using Equation 3-8, we 
calculate this distance under the assumption of free fluorescent protein rotation (an 
assumption that may not be correct). The relative positioning of the fluorescent proteins, 
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and thus the general dimer architecture, is similar for five of the dimers. In contrast, the 
inter-fluorophore distance is larger in the FGFR1•FGFR3 heterodimer, suggesting an 
increase in the separation of the TM domain C-termini relative to the other dimers. 
We further examine six mutant FGFR heterodimers (Table 5-2 and Figure 5-6). 
The Achondroplasia heterodimers FGFR1•FGFR3_G380R, FGFR2•FGFR3_G380R, and 
FGFR3•FGFR3_G380R have stabilities of -5.2 ± 0.1, -4.7 ± 0.3, and -5.2 ± 0.1 kcal/mol, 
respectively. The Crouzon syndrome heterodimers FGFR1•FGFR3_A391E, 
FGFR2•FGFR3_ A391E, and FGFR3•FGFR3_ A391E have stabilities of -5.3 ± 0.2, -4.5 
± 0.2, and -5.1 ± 0.1 kcal/mol, respectively. 
To compare the wild-type and mutant heterodimers, t-tests are performed on the 
dimer stability and Intrinsic FRET values. The difference between wild-type and mutant 
dimer stabilities, ∆∆GXY, is calculated to assess the effects of mutations on the 
thermodynamics of dimer formation. Analogously, the difference in Intrinsic FRET 
values, ∆Ẽ, is computed to estimate any alteration in dimer architecture.   
First, we consider the FGFR1•FGFR3 heterodimer. The Achondroplasia and 
Crouzon syndrome mutations both stabilize this heterodimer, by -0.4 ± 0.1 and -0.5 ± 0.1 
kcal/mol, respectively. Additionally, the Achondroplasia mutation increases the Intrinsic 
FRET value.  
 Next, we turn to the FGFR2•FGFR3 heterodimer. We find that the 
Achondroplasia mutation stabilizes the dimer by -0.6 ± 0.1 kcal/mol and has no effect on 
Intrinsic FRET. The differences between the wild-type and Crouzon syndrome 
FGFR2•FGFR3 heterodimers are not statistically significant. 
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 The wild-type\mutant FGFR3 heterodimer is slightly different from those 
described thus far, which all form between two different FGFRs. This heterodimer forms 
between a wild-type FGFR3 and a FGFR3 with a pathogenic point mutation (either 
G380R or A391E), and comparisons are made to the wild-type FGFR3 homodimer. The 
Achondroplasia mutation stabilizes the dimer by -1.8 ± 0.1 kcal/mol. The Crouzon 
syndrome mutation also has a stabilizing effect, with a ∆∆GXY of -1.7 ± 0.1 kcal/mol. 
Both mutations also decrease the Intrinsic FRET value, suggesting that the fluorescent 
proteins are further apart in the wild-type\mutant FGFR3 heterodimers than in the wild-
type FGFR3 homodimer. 
Discussion 
We introduce a new methodology to study RTK heterodimerization 
 Membrane proteins are notoriously challenging to study (7), and detailed 
information about membrane protein interactions and structure is elusive, despite active 
research in the field (8,131-133). The need for new basic knowledge is underscored by 
the fact that approximately 60% of all FDA-approved therapeutics target membrane 
proteins (6). Biophysical information about drug targets can yield better mechanistic 
understanding of their function, and ultimately allows for more accurate prediction of 
drug action and function. 
 Recently, advances in microscopy have complemented the biochemical assays 
traditionally used in membrane protein research, producing new insights about membrane 
protein function (46,54,77,105,106,108,134,135). In this paper, we build on our previous 
work to develop and implement a quantitative FRET assay for examining RTK 
heterodimers. The method yields the apparent heterodimer association constant, KXY, and 
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a conformational parameter (Intrinsic FRET, or Ẽ), which has been previously used to 
assess if structural changes occur in RTK dimers due to ligand binding or mutations 
(18,19,34,118,119). 
 Compared to biochemical methods, FRET offers unique advantages for 
examining heterodimers. We label one receptor with a FRET donor and the other with a 
FRET acceptor, so heterodimers have both a donor and acceptor, while homodimers have 
either two donors or two acceptors.  Thus, FRET occurs only when heterodimers form. 
Methods such as SDS-PAGE and Western blotting, on the other hand, struggle to 
distinguish between RTK homodimers and heterodimers. Challenges arise because 
receptors are similar in size, so the two complexes cannot be distinguished on a gel. 
While immunoprecipitation can report on heterodimer formation, it is limited to 
qualitative observations and requires the removal of the receptors from the native 
membrane. Furthermore, in many biochemical methods, the propensity for dimer 
formation and the structure of that dimer are both known to affect experimental read-outs, 
but their respective contributions usually cannot be separated. The FRET technique 
described here can report on heterodimer formation in an intact membrane and can 
uncouple thermodynamic from structural information. However, the receptors are 
attached to bulky fluorescent proteins, which may perturb interactions in some cases. 
Furthermore, heterodimerization propensities can only be determined when the 
homodimerization propensities have already been measured. Finally, no FRET will be 
detected if the distance between the two fluorophores in the dimer complex exceeds 100 
Å, even if a stable dimer forms. 
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Similar FRET techniques have been discussed in the literature (30,121,136), but 
the methodology presented here improves on previous work in multiple ways. 
Experiments are performed in cell-derived vesicles that capture many features of the 
native environment (43,44). These vesicles closely mimic the diverse lipid and protein 
content of the plasma membrane (44). The receptors are transiently expressed in the cells 
prior to vesiculation, so they undergo all relevant post-translational modifications, 
including glycosylation. In contrast, the previous heterodimerization studies were 
performed in synthetic lipid vesicles and limited to TM domain peptides. 
In previous work on heterodimerization in membranes, the ratio between 
receptors has been held constant to simplify data analysis (30,121,129,130,136). The 
approach that we present has no such limitations and is applicable in cases where the 
ratio between receptors cannot be controlled, as in cellular studies. The new method is 
quantitative, yielding heterodimer association constants, despite being performed in a 
complex system that mimics the native environment. Thus, this FRET method can have 
broad utility in membrane protein research, as it can be used to study the 
heterodimerization propensity of any two membrane proteins. 
Wild-type FGFR homodimers and heterodimers have similar stabilities and Intrinsic 
FRET values 
 Biochemical methods have previously shown that FGFR heterodimers form and 
are enzymatically active in cells, in the presence of ligand (21,117,137,138), but the 
thermodynamics of the association process have not been quantified. Furthermore, FGFR 
heterodimerization in the absence of ligand has never been investigated. Here, we 
observe unliganded FGFR heterodimers and for the first time measure the 
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thermodynamic stability of these heterodimers in the plasma membrane. In the absence of 
ligand, the propensity for heterodimer formation is similar to or larger than that of 
homodimers (see Table 5-1 and Figure 5-6). When combined with information about the 
cell’s receptor concentrations, such dimer stabilities can empower prediction of 
homodimer and heterodimer populations. Therefore, this work can further our 
understanding of FGFR signaling, which is regulated by the formation of different dimers 
with unique functions (117,137,138). 
 In this set of experiments, we work with receptors that lack the IC domain, which 
is replaced with a fluorescent protein on a flexible linker. These truncated receptors can 
be expressed in a broad concentration range, a requirement for a successful fit of the 
model to the data, thereby facilitating method development (55). Additionally, the 
truncation of the receptors increases the likelihood that fluorophores attached to FGFRs 
in a heterodimer will undergo FRET. RTKs are known to have long unstructured C-
terminal tails, and in some cases, this means that fluorescent proteins attached to full-
length receptors in a dimer are too far apart to undergo FRET (139). 
Contacts between IC domains generally promote, and never inhibit, RTK dimer 
formation (18,19,140-143). Indeed, full-length RTKs have been shown to have stronger 
propensities for lateral interactions than RTK constructs that lack the IC domain (18). In 
our previous work with FGFR dimer formation, we measured the contribution of the IC 
domain to FGFR1, FGFR2, and FGFR3 homodimerization as ~0, -2, and -3 kcal/mol, 
respectively (18). We expect heterodimer behavior to be similar. Accordingly, our 
finding that the truncated FGFRs engage in heterodimeric interactions suggests that full-
length receptors will also form heterodimers. Furthermore, we expect that the stability of 
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full-length FGFR heterodimers is likely similar to or larger than that measured for 
truncated FGFR heterodimers. 
The Achondroplasia and Crouzon syndrome mutations show their largest effects on the 
stability of the FGFR3 dimer 
Table 5-2 summarizes the changes observed in the FGFR heterodimers due to the 
Achondroplasia and Crouzon syndrome mutations. The thermodynamics of 
heterodimerization are perturbed in five of six cases. The largest effects are measured on 
the dimer stability in the wild-type\mutant FGFR3 dimer. Indeed, the Achondroplasia and 
Crouzon syndrome mutations stabilize this heterodimer by -1.8 ± 0.1 and -1.7 ± 0.1 
kcal/mol, respectively. These stabilizations are comparable to those measured for the 
mutant FGFR3 homodimers (118,119), suggesting that both mutant homodimers and 
mutant heterodimers may be important signaling entities in the two developmental 
disorders. The effects on the FGFR1•FGFR3 and FGFR2•FGFR3 heterodimers, on the 
other hand, are relatively small. The Achondroplasia mutation stabilizes these two 
heterodimers by -0.4 ± 0.1 and -0.6 ± 0.1 kcal/mol, respectively. The Crouzon syndrome 
mutation stabilizes FGFR1•FGFR3 by -0.5 ± 0.1 kcal/mol and has no effect on 
FGFR2•FGFR3. These stabilizations rank among the smaller ΔΔG values that we have 
measured for pathogenic point mutations in FGFRs (34,118,119), although these changes 
might still contribute to the development of the skeletal disorders studied here. 
 For three of the mutant heterodimers, we observe a statistically significant change 
in Intrinsic FRET, most likely due to a change in the separation of the fluorescent 
proteins in the heterodimer. While the details of how RTK dimer architecture relates to 
function remain obscure, it is clear that TM domain structure plays a fundamental role in 
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determining signaling properties (102,103). It is possible that the structural effects 
(observed as changes in Intrinsic FRET) captured in these experiments influence cross- 
phosphorylation in the heterodimer and potentially contribute to the two phenotypes. 
It has been suggested that the phenotypical differences observed between 
Achondroplasia and Crouzon syndrome with acanthosis nigricans might be explained if 
one of the mutations primarily affects  homodimerization, while the other mostly 
influences heterodimerization (24,116). Our results are inconsistent with this idea, instead 







































Figure 5-2. Theoretical predictions of the heterodimerization model, as a function of the 
concentration of the two receptors. 
This model is based on a coupled system of equations describing the formation of the 
homodimers XX and YY and the heterodimer XY (see Equations 5-1 & 5-2), as well as 
the mass conservation of the receptors (Equations 5-3 & 5-4). The solution of this system 
is the heterodimerization model (Equation 5-5), and predictions from this equation are 
graphed here.  The dimer fraction depends on the concentration of each receptor species 
([Xtotal] and [Ytotal]) and all three association constants (KX, KY, and KXY). KX and KY are 
increased from top to bottom. The left-hand panels display total dimer fraction (Equation 
5-6) as a cyan surface with contour lines, and the right-hand panels display the fractional 
contribution of each dimer species [XX], [YY], and [XY] (Equation 5-7) as violet, pink, 
and white surfaces, respectively. In these plots, we assume a heterodimer association 
constant of 850*10-6 um2/rec (∆GXY = -4.0 kcal/mol). The homodimer association 
constants  are varied by an order of magnitude from (a) KX,1 = 100*10-6 um2/rec and KY,1 
= 500*10-6 um2/rec to (b) KX,2 = 10*KX,1 and KY,2 = KY,1 to ‘(c) KX,3 = KX,1 and KY,3 = 
10*KY,1 to (d) KX,4 = 10*KX,1 and KY,4 = 10*KY,1.  


























































































































































 86   
 
























































































































































 87   
 
























































































































































 88   
 
Figure 5-3. Vesicle FRET data for the (A-C) wild-type and (D-I) mutant FGFR 
heterodimers. 
The dark blue right-pointing triangles, purple up-pointing triangles, green left-pointing 
triangles, light blue diamonds, and black squares represent the FGFR1, FGFR2, FGFR3, 
FGFR3_G380R, and FGFR3_A391E homodimer FRET data (18,34,118,119). Data 
collected during heterodimer FRET experiments are always shown with red circles. For 
both homodimer and heterodimer data, each point represents a single vesicle. In the left-
hand panels, the measured FRET efficiencies are plotted as a function of acceptor 
concentration. Proximity FRET, or the FRET due to non-specific close approach of two 
receptors, is shown as a black line (77,82). The measured FRET efficiencies exceed 
proximity FRET in every case, which suggests that specific heterodimeric interactions 
occur for all heterodimers investigated. In subsequent analysis, the measured FRET 
efficiency is corrected for proximity FRET to find the dimer-specific FRET efficiency. In 
the right-hand panels, donor concentrations are plotted against acceptor concentrations. 
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Figure 5-4. Experimentally determined and theoretically predicted heterodimer 
concentrations [XY], as a function of the two receptor concentrations. 
The model is plotted as a yellow surface with contour lines and experimentally 
determined values are shown as blue (points above model surface) or red (points below) 
circles. Experimental heterodimer concentrations are calculated according to Equation 
5-9 and theoretical predictions are made using Equation 5-5. The best fit values are 
plotted here for the (A-C) wild-type, (D-E) Achondroplasia, and (G-I) Crouzon syndrome 
FGFR heterodimer pairs.  
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Figure 5-5. Total dimer fractions for wild-type and mutant FGFR heterodimers. 
Equation 5-6 is used to calculate the total dimeric fraction, fD, as a function of the 
receptor concentrations. Experimental data (purple circles) is compared to the best fit 
heterodimerization model (cyan surface with contour lines). Shown are results for the (A-
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    Dimer Stability Dimer Conformation 














a (2336 ± 484) * 10-6 -4.6 ± 0.1 0.50 ± 0.03 53.1 ± 0.7 
FGFR2a (309 ± 57) * 10-6 -3.4 ± 0.1 0.57 ± 0.04 50.7 ± 1.0 
FGFR3a,b (309 ± 65) * 10-6 -3.4 ± 0.1 0.52 ± 0.03 52.4 ± 1.0 
FGFR3_G380Rc (6430 ± 1212) * 10-6 -5.2 ± 0.1 0.59 ± 0.01 50.0 ± 0.4 








FGFR1•FGFR2 (2109 ± 379) * 10-6 -4.5 ± 0.1 0.52 ± 0.04 52.3 ± 1.3 
FGFR1•FGFR3 (3540 ± 432) * 10-6 -4.8 ± 0.1 0.38 ± 0.02 57.4 ± 0.6 
FGFR2•FGFR3 (988 ± 308) * 10-6 -4.1 ± 0.2 0.53 ± 0.05 52.0 ± 1.9 
FGFR1•FGFR3_G380R (6428 ± 1302) * 10-6 -5.2 ± 0.1 0.51 ± 0.06 52.6 ± 2.0 
FGFR2•FGFR3_G380R (2829 ± 1207) * 10-6 -4.7 ± 0.3 0.73 ± 0.20 43.5 ± 9.7 
FGFR3•FGFR3_G380R (6435 ± 180) * 10-6 -5.2 ± 0.1 0.37 ± 0.01 57.9 ± 0.4 
FGFR1•FGFR3_A391E (8463 ± 2715) * 10-6 -5.3 ± 0.2 0.48 ± 0.08 53.7 ± 2.9 
FGFR2•FGFR3_A391E (2106 ± 714) * 10-6 -4.5 ± 0.2 0.78 ± 0.18 41.6 ± 8.6 
FGFR3•FGFR3_A391E (5356 ± 551) * 10-6 -5.1 ± 0.1 0.40 ± 0.02 56.7 ± 0.8 
 
Table 5-1. Optimal parameters describing FGFR homodimerization and 
heterodimerization. 
Previously published homodimer results (top of table) (18,118,119) are used to solve 
Equation 5-10, which describes heterodimer formation in FRET experiments. The 
heterodimer results (bottom of table) are listed as averages and standard deviations, as 
calculated using the bootstrap method (see the Heterodimerization Model section for 
details). Dimer stability, ∆G, is calculated from the association constant using Equation 
3-3. Under the assumption of freely rotating fluorophores, the distance between 
fluorescent proteins in a dimer, d, is estimated using Equation 3-8. 
aData from (18) 
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bData from (34) 
cData from (119) 
dData from (118) 
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  Dimer Stability Dimer Conformation 
 
ΔΔG (kcal/mol) p-value Δ Ẽ p-value 
FGFR1•FGFR3_G380R -0.4 ± 0.1 0.024 ↑ 0.13 0.021 
FGFR1•FGFR3_A391E -0.5 ± 0.1 0.016 ns 0.103 
FGFR2•FGFR3_G380R -0.6 ± 0.1 0.034 ns 0.173 
FGFR2•FGFR3_A391E ns 0.060 ns 0.0797 
FGFR3•FGFR3_G380R -1.8 ± 0.1 0.000107 ↓ 0.15 0.0146 
FGFR3•FGFR3_A391E -1.7 ± 0.1 0.000202 ↓ 0.12 0.0365 
 
Table 5-2. Effects of the Achondroplasia and Crouzon syndrome mutations on FGFR 
heterodimerization. 
Unpaired t-tests are performed for the null hypothesis that the wild-type and mutant 
heterodimers are the same, and the resulting p-values are shown. “ns” indicates that any 
measured difference is not significant. The largest stabilization effects are observed in 
wild-type\mutant FGFR3 dimers, and these ∆∆G values are accompanied by decreases in 
Intrinsic FRET. FGFR1•FGFR3 is slightly stabilized by each mutation and also 
experiences an increase in Intrinsic FRET for the Achondroplasia mutation only. The 
only statistically significant change in FGFR2•FGFR3 due to the presence of a mutation 
is a small increase in stability in the presence of the Achondroplasia mutation. 
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CHAPTER SIX Characterization of the Interaction Between EGFR and Grb2 in 
Live Cells 
RTK-Adapter Protein Interactions and EGFR-Grb2 
 Despite having no inherent activity, adapter proteins play an essential role in 
cellular signaling networks. These small proteins are composed of highly specific, 
modular binding domains (ie, SH2 and PTB domains), and are responsible for mediating 
many protein-protein interactions. In the special case of RTKs, adapter proteins such as 
Grb2, Shc, and Nck bind to phosphorylated residues in the IC domain, initiating the 
recruitment and activation of other cytoplasmic proteins and triggering downstream 
signaling cascades, including the MAPK, PI3K, PKC, and STAT pathways 
(4,11,12,144,145).  
 Many RTKs are over-expressed and over-active in tumor tissue, and adapter 
proteins are the direct link between receptors and biological activity. Hence, a class of 
anti-cancer drugs, Tyrosine Kinase Inhibitors (TKIs), has been developed to specifically 
disrupt the interaction between RTKs and adapter proteins, and thereby eliminate 
aberrant RTK activity. TKIs like Gefitinib can improve patient outcomes, but their 
efficacy has fallen short of initial projections (15,28). Many TKIs are small molecules 
that were discovered through in vitro screenings conducted with short peptides 
representing the adapter protein and the phosphorylated RTK IC domain (146,147). An in 
vivo model system of RTK-adapter protein interactions would be a valuable experimental 
tool, allowing for screening of TKIs in a system consisting of full-length receptors and 
adapter proteins.  
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 Here, we present an in vivo model system for the study of RTK-adapter protein 
interactions. In this system, live cells are placed under reversible osmotic stress using a 
hypotonic buffer. In these swollen cells, the membrane is stretched out, eliminating its 
complex topology, and the cytoplasm is retained. This combination of a model membrane 
in the presence of the cytoplasm allows for the study of interactions between membrane 
proteins and soluble proteins.  
 In the canonical model of RTK activation, ligand binding induces dimer 
formation, followed by cross-phosphorylation of the IC domains and recruitment of 
adapter proteins (4,11). Indeed, previous studies show that recruitment of adapter proteins 
to the IC domain of RTKs increases following ligand addition (139,147-150). However, 
emerging evidence suggests that, even in the absence of ligand, RTKs form dimers 
(18,19) and that some of these unliganded dimers are active (5,151). The phosphorylation 
level of these unliganded RTK dimers remains an open question, but can be assessed by 
monitoring the recruitment of adapter proteins to RTKs in the absence of ligand. 
 Here, we study the interaction between the RTK EGFR and the adapter protein 
Grb2. Following receptor activation, Grb2 is recruited to the tail of EGFR and mediates 
the receptor's connection to the MAPK signaling pathway. This interaction takes place 
through Grb2's SH2 domain, which binds to the phosphorylated Y1068 and Y1086 
residues of EGFR (5,10,15,139,152). Of the many possible pairs of receptors and adapter 
proteins, EGFR and Grb2 were selected because i) the recruitment of Grb2 to EGFR 
following phosphorylation has been well-documented (147,148,150,152-157) and ii) the 
interaction can be observed via FRET (139,149,158). These two characteristics make the 
EGFR-Grb2 binding reaction a suitable model system in which to develop and implement 
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the new FRET microscopy method reported here. Experiments are performed in the 
absence and presence of the ligand EGF. We obtain parameters describing both the 
thermodynamics of the EGFR-Grb2 interaction and the level of unliganded EGFR dimer 
phosphorylation. 
Model to Describe RTK-Adapter Protein Interactions 
 Thermodynamic cycles are an increasingly popular way to describe and model the 
RTK activation process (123,159). In this work, we present a thermodynamic cycle for 
RTK activation that includes dimer formation, ligand binding, phosphorylation, and 
adapter protein binding (see Figure 6-1). We depict unliganded receptors as open black 
squares, liganded receptors as filled black squares, phosphorylation as filled red circles, 
and adapter proteins as filled green arcs. Equilibrium reactions occur between two 
receptors (αi), upon dimer phosphorylation (βi), between receptors and adapter proteins 
(γi), and upon ligand binding (εi).  
 In Chapter Three, Chapter Four, and Chapter Five, we examined interactions 
between two receptors. In this chapter, we focus on receptor phosphorylation and the 
interaction between a receptor and a soluble protein. We continue to use a monomer-
dimer equilibrium model to describe the interaction of two receptors, and we consider the 
binding reaction between monomeric ligands and receptors as an equilibrium process 
(159).   
 Receptor phosphorylation only occurs within dimers (5,123). When ligand binds 
to an RTK dimer, a conformational change occurs in the kinase domains of the receptors. 
Specifically, the kinase domains adopt an active asymmetric configuration, which allows 
for phosphorylation and subsequent interactions with adapter proteins and other soluble 
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proteins. Here, we model this process as a conformational change from an inactive dimer 
(D) to an active dimer (D*): 
    
 
       (6-1). 
The equilibrium constant describing this conformational change, β, can be written as: 
     
  
   
  (6-2) 
where [D] and [D*] are in two-dimensional units of proteins/μm2 and β has no units. 
 The interaction between a membrane protein and a soluble protein is an 
equilibrium reaction that has been previously described (160-163). In the special case of 
the adapter protein-RTK system, adapter proteins (A) only bind to phosphorylated 
dimers: 
      
 
       (6-3) 
where D*A is the complex formed by a phosphorylated dimer and adapter proteins, and n 
is the number of adapter proteins bound to each dimer. The association constant γ can be 
written as: 
     
    
        
  (6-4) 
where [D*] and [D*An] are in two-dimensional units of proteins/μm2, [A] is in three-
dimensional units of proteins/μm3, and γ is in units of μm3/protein.  
 Here, experiments are performed in swollen cells. In swollen cells, endocytosis is 
inhibited (50), so mass conservation of receptors can be employed: 
                             (6-5) 
where T and M denote total receptors and monomers, respectively. In this model, the 
concentration of adapter proteins in the cytoplasm is high, so it is an unlimited pool of 
binding molecules and can be considered as a constant. Equation 6-5 can be used in 
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conjunction with the thermodynamic equilibrium equations to characterize the parameters 
of the RTK activation cycle. 
 Finally, we can calculate the fraction of receptors found in each species:  
    
   
   
  
    
    
   
  
     
     
   
  
       
       
   
  (6-6). 
where fM, fD, fD*, and fD*An denote the fraction of receptors that exist as monomers, in 
inactive dimers, in active dimers, and in dimer-adapter protein complexes, respectively. 
Interpretation of FRET Data 
 The receptor is labeled with a FRET donor and the adapter protein is labeled with 
a FRET acceptor. If an adapter protein binds to a receptor, FRET will occur. The 
concentration of the donor (equivalently, the receptor), the acceptor (or, the adapter 
protein), and the FRET efficiency (E) can be measured using the FSI technique (46). 
FRET efficiency, which is defined in terms of change in donor fluorescence, can be 
directly related to the formation of the dimer-adapter protein complex (121,126,127) 
according to: 
     
            
       
  (6-7) 
where Ecomplex is a geometrical parameter that depends on the separation and orientation 
of the two fluorophores in the dimer-adapter protein complex. Specifically, Ecomplex is the 
FRET efficiency in a dimer-adapter protein complex. This geometrical parameter must be 
determined and accounted for, in order to correctly interpret FRET data.  
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 Ecomplex depends on the oligomeric size and geometric configuration of the dimer-
adapter protein complex. Here, we consider the pairwise FRET efficiency between a 
donor and an acceptor, Ep, and follow the approach of Raicu and Singh (164) to calculate 
Ecomplex as a function of Ep for various oligomeric sizes and goemetric configurations of 
[D*An]. Since the number of adapter proteins, n, in each dimer-adapter protein complex 
is still under debate, we consider Ecomplex for n = 0, 1, 2, 3, and 4. The geometrical 
configurations we consider are depicted in Figure 6-2, and the Ecomplex values as a 
function of Ep are listed next to each configuration. 
Results 
 We use the thermodynamic cycle for RTK activation described above to 
characterize both the phosphorylation of EGFR dimers and the interaction between 
EGFR and Grb2. We engineer plasmids coding for full-length EGFR fused to a flexible 
GGS linker followed by mTurquoise (a FRET donor) and full-length Grb2 followed by 
GGS and YFP (a FRET acceptor). Earlier studies have verified that the interaction 
between EGFR and Grb2 is observable in this experimental design (139,158). 
 CHO cells are co-transfected with the EGFR and Grb2 plasmids. After 24 hours, 
the full cell culture media is removed and replaced with a limited cell culture media that 
lacks growth factors. Starving the CHO cells in this manner eliminates the presence of 
any natively-expressed EGFR ligands. Twelve hours later, the media is again replaced, 
this time with so-called "swelling media". This buffer causes CHO cells to swell (see 
Figure 2-1, Panel B) in a reversible process that stretches and unwrinkles the plasma 
membrane, enabling accurate measurements of donor concentration, acceptor 
concentration, and FRET efficiency in the membrane of live cells (46). For experiments 
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in the presence of ligand, swelling media is supplemented with 300 nM EGF and 1 
mg/mL BSA.  
 CHO cells equilibrate with the hypotonic buffer for 20 minutes, and then are 
imaged using the FSI method (46). In the FSI method, the cross-section of each cell is 
imaged twice: once at the excitation of the donor (840 nm) and again at the excitation of 
the acceptor (960 nm). The microscope is calibrated using solutions of free fluorescent 
protein and CHO cells transfected with only the donor-labeled receptor or the acceptor-
labeled adapter protein. This calibration empowers pixel-level deconvolution of measured 
fluorescence spectra to fluorophore concentrations and FRET efficiency. In these 
experiments, two regions were selected in each swollen cell: a membrane region and a 
cytoplasmic region. We measure three quantities per pair of regions. In the membrane 
region, we measure i) the concentration of the donor (equivalently, the receptor) and ii) 
the FRET efficiency. In the cytoplasmic region, we measure iii) the concentration of the 
acceptor (equivalently, the adapter protein). See Figure 2-3, Panel B for an example of a 
swollen cell analyzed using FSI.  
 Here, we use this FRET data to consider two special cases of this thermodynamic 
cycle: saturating ligand conditions and ligand-free conditions. In both cases, the model in 
Figure 6-1 reduces substantially, allowing us to determine some of the parameters 
characterizing the system. 
In the presence of ligand, the thermodynamics of the binding reaction between Grb2 and 
EGFR be quantified in live cells  
 In the first special case of the thermodynamic cycle of RTK activation (circled in 
blue in Figure 6-1), we consider receptor-adapter protein interactions under saturating 
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ligand conditions. We assume that, in the presence of excess ligand, all receptors exist as 
double-liganded, phosphorylated dimers. Since all receptors are found as phosphorylated 
dimers, the mass conservation equation (Equation 6-5) can be reduced to: 
                   (6-8). 
The relationship between liganded, phosphorylated RTK dimers bound and unbound  to 
the adapter protein is governed by the association constant γ2 (Equation 6-4). If we 
substitute this equilibrium relationship into Equation 6-8, we arrive at a single equation 
that describes the interaction between receptors and adapter proteins: 
    
 
 
       
      
          (6-9). 
Note that the concentration of dimer-adapter protein complexes, [D*An], depends on the 
variables [T] and [An] and the parameter γ2.  
 To facilitate comparison of this model with FRET data, we rearrange Equation 
6-7 to describe [D*An] as a function of FRET efficiency:  
        
        
        
  (6-10) 
and substitute into Equation 6-9 to find: 
    
 
  
        
        
   
 
     
     (6-11). 
The quantities [donor], [A], and E are all measured in FSI experiments. Non-linear least 
squares (128,165) (MATLAB's "nlinfit") is used to fit Equation 6-11 to experimental 
data, yielding the association constant, γ2, and the geometrical parameter, Ecomplex, and 
their 95% confidence intervals. This fitting process is repeated for the possible receptor-
adapter protein complex stoichiometries and geometries described in Figure 6-2. For each 
number of adapter proteins, n, we calculate the mean square error (MSE) between the 
best fit model and the experimental data according to: 
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  (6-12) 
where k is the number of pairs of regions, FRETex,i is the experimentally measured FRET 
efficiency, and FRETth,i is theoretical FRET efficiency (predicted by Equation 6-7). The 
value of n that minimizes the MSE is taken as the number of adapter proteins per dimer-
adapter protein complex. 
 In Figure 6-3, we show data for the EGFR-Grb2 binding reaction, collected under 
saturating ligand conditions. Panel A displays the experimentally measured receptor 
concentration, adapter protein concentration, and FRET efficiency. In the left-hand plot, 
FRET efficiency is plotted as a function of acceptor concentration. The steep dependence 
of FRET efficiency on acceptor concentration suggests the occurrence of specific 
interactions. In the right-hand plot, we graph donor concentration versus acceptor 
concentration. For both plots, each green diamond corresponds to data from one pair of 
membrane and cytoplasmic regions in a swollen cell. An average of two pairs of regions 
are selected per cell.  
   Next, we compare this data to the thermodynamic cycle for RTK activation, in 
the limiting case of saturating ligand conditions (circled in blue in Figure 6-1). We fit 
Equation 6-11 to the experimental data while varying the number of adapter proteins per 
complex, n. Each fit yields the association constant between active EGFR dimers and Grb 
proteins, γ2, and the geometrical FRET parameter, Ecomplex. In Panel C, we show the MSE 
(calculated according to Equation 6-12) for each n. The minimum MSE corresponds to n 
= 1, which suggests that there is one Grb2 protein bound to each EGFR dimer. We use 
this result for all subsequent analyses. 
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 Here, we report the parameters describing adapter protein binding to RTK dimers 
when n = 1. The association constant between phosphorylated EGFR dimers and Grb2 
proteins is γ2 = (5.95 ± 0.7)x10-3 μm3/protein and the FRET efficiency in the dimer-
adapter protein complex is Ecomplex = 0.640 ± 0.02. The best fit receptor-adapter protein 
model (yellow surface) is plotted alongside experimental data (green diamonds) in Panel 
C. The model and data are plotted on a linear scale in the left-hand plot and on a semi-log 
scale in the right-hand plot.  
 To further illustrate how the thermodynamic cycle for RTK activation behaves 
under saturating ligand conditions, Panel D displays the fraction of receptors found in 
active dimers (red line) and in dimer-adapter protein complexes (yellow line) for the best 
fit parameters. In the left-hand plot, the adapter protein concentration, [A], is fixed at 500 
proteins/μm3 and the total receptor protein concentration, [T], is varied between 0 and 
1000 receptors/μm2. In the right-hand plot, [T] is fixed at 500 proteins/μm3 and [A] is 
varied between 0 and 1000 receptors/μm2. The fraction of receptors found in dimer-
adapter protein complexes increases as the adapter protein increases but shows no 
dependence on total receptor concentration. 
In the absence of ligand, some EGFR dimers are phosphorylated 
 In the second special case of the thermodynamic cycle of RTK activation (circled 
in yellow in Figure 6-1), we consider receptor-adapter protein interactions in the absence 
of ligand. We must consider monomers, inactive dimers, active dimers, and dimer-
adapter protein complexes. For the analysis presented here, the monomer-dimer 
equilibrium constant, α0, must have been previously measured (here, we use α0 = 6.8x10-3 
μm2/rec, as measured by Daniel Leahy's lab in unpublished work). We assume that the 
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binding reaction between active dimers and adapter proteins is independent of ligand 
(that is, γ2 = γ0 and the geometrical parameter Ecomplex is the same as that measured under 
saturating ligand conditions). Thus, the only remaining unknown is β0, the 
conformational parameter describing the relationship between inactive and active dimers. 
 We can use the thermodynamic relationships in Equations 3-2, 6-2, and 6-4 to 
relate the concentrations of receptor species to each other: 
             
             
                    (6-13). 
Using the relationships in Equation 6-13, we can write the mass conservation equation in 
terms of monomer concentration only: 
                                            (6-14) 
where α0, β0, and γ0, and n are all known. We can solve for [M] as a function of [A] and 
[T] using the quadratic formula (125). Then, we can substitute into the three statements in 
Equation 6-13 to find the concentrations of the other three receptor species.  
 We use Equation 6-10 to calculate the concentration of the receptor-adapter 
protein complex [D*An] from the FRET efficiency. Combining the relationships in 
Equation 6-13, [D*An] can also be written as 
                        (6-15) 
and this equation can be set equal to [D*An] as calculated from the FRET efficiency. 
Hence, we are left with two equations, 6-14 and 6-15, and two unknowns, β0 and [M]. 
Non-linear least squares (MATLAB's "nlinfit") is used to simultaneously solve for [M] 
and fit for β0 and its 95% confidence interval.  
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 Data collected for EGFR-Grb2 interactions in the absence of ligand are presented 
in Figure 6-4. Panel A displays the experimentally measured receptor concentration, 
adapter protein concentration, and FRET efficiency. The left-hand plot shows FRET 
efficiency as a function of acceptor concentration. FRET efficiency increases with 
increasing acceptor concentration, but the dependence is less pronounced than that 
observed in the presence of ligand. Donor concentration versus acceptor concentration is 
plotted in the left-hand panel. Each green diamond corresponds to a pair of membrane 
and cytoplasmic regions. 
 We compare this experimental data to the thermodynamic cycle for RTK 
activation, in the absence of ligand. Here, we find β0 = 1.05 ± 0.3. In Panel B, the best fit 
model for [D*An] (yellow surface) is plotted alongside experimental data (green 
diamonds) on a linear scale (left-hand plot) and a semi-log scale (right-hand plot).  
 Panel C demonstrates how the thermodynamic cycle for RTK activation behaves 
in the absence of ligand. The fraction of receptors found as monomers (green line), 
inactive dimers (blue line), active dimers (red line), and dimer-adapter protein complexes 
(yellow line) are plotted as functions of the two variables [T] and [A], using the 
parameters for the best fit model. In the left-hand panel, adapter protein concentration is 
fixed at 500 proteins/μm2 while [T] varies, and in the right-hand panel, total receptor 
concentration is fixed at 500 receptors/μm2 while [A] varies. The fraction of receptors 
found in each species depends on both adapter protein concentration and total receptor 
concentration. 
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Discussion 
 The interaction between RTKs and adapter proteins has been studied extensively. 
These experiments can generally be sorted into two broad categories: traditional 
biophysical methods (152,156,157,161) and emerging cell-based techniques 
(139,147,148,163). In the first category of experiments (162,166), fluorescence 
spectroscopy, FRET, surface plasmon resonance, and isothermal titration calorimetry 
have all been used to characterize RTK-adapter protein interactions, yielding quantitative 
measures of thermodynamic and/or kinetic binding parameters. However, these 
traditional biophysical techniques require reducing the system to short peptides 
representing the RTK and adapter protein. Furthermore, they use synthetic lipids or 
surface display of RTK peptides to model the membrane, and are sometimes conducted in 
solution. In the second category of experiments, live cells are an increasingly popular 
model system for the study of protein-protein interactions, and they capture the native 
complexities of both the plasma membrane and the cytoplasm. These experiments 
incorporate full-length RTKs and adapter proteins, but typically consist of qualitative 
observations of adapter protein recruitment to receptors. In this work, we combine the 
quantitative power of traditional biophysical techniques with the biological relevance of 
live cell model systems and measure the thermodynamic association constant between a 
receptor and an adapter protein. This new method can be used to quantify RTK-adapter 
protein interactions and as a screening platform for TKIs. 
 Here, we examine the interaction of EGFR and Grb2. The SH2 domain binds to 
the phosphorylated Y1068 and Y1086 residues of EGFR (156,157). The stoichiometry of 
this reaction is debated in the literature (148,149,155), with estimates ranging between 
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one and four Grb2 proteins per EGFR dimer. We fit models with one, two, three, or four 
Grb2 proteins per EGFR dimer to our experimental data, and find the best fit for the 
model with one Grb2 protein per EGFR dimer. The model of one adapter protein per 
dimer seems reasonable in the context of both geometrical considerations and the current 
literature (5,153,154). 
 We characterize the thermodynamics of EGFR-Grb2 binding interactions under 
saturating ligand conditions. The high ligand concentration ensures that all receptors exist 
as dimers (167), and we assume that all of these dimers are phosphorylated. The 
association constant is measured as γ2 = (5.95 ± 0.7)x10-3 μm3/protein, equivalent to 279 
± 34 nM. This value is of the same order of magnitude as was previously measured using 
traditional biophysical techniques (5). We also report Ecomplex, a geometrical parameter 
that depends on the separation of the fluorescent proteins in the EGFR-Grb2 complex. 
The fluorophores are attached to the C-terminus of each protein, and we measure Ecomplex 
= 0.640 ± 0.02. This corresponds to a fluorophore separation of 49.5 ± 0.7 Å in the 
receptor-adapter protein complex. This distance was calculated using Equation 3-8 and 
the Förster radius for the mTurquoise-YFP FRET pair (54.5 Å), under the assumption of 
free fluorophore rotation. 
 We also examine the EGFR-Grb2 binding interaction in the absence of ligand, in 
order to estimate the equilibrium between inactive (D) and active (D*) EGFR dimers. 
There is a literature consensus that some unliganded EGFR dimers are phosphorylated 
(5,15,147), but very few quantitative estimates for the relationship between D and D*. 
This is most likely due to a scarcity of experimental techniques capable of specifically 
measuring phosphorylation. Here, we leverage our newly developed FRET microscopy 
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technique to observe EGFR phosphorylation in live cells, through the recruitment of the 
adapter protein Grb2. We employ the two parameters describing RTK-adapter protein 
interactions measured under saturating ligand conditions, and the full-length EGFR 
homodimer association constant, to determine that the conformational parameter 
describing the equilibrium between D and D* is β0 = 1.05. This result indicates that, in 
the absence of ligand, approximately one-half of EGFR dimers are phosphorylated. Our 
estimate for unliganded EGFR phosphorylation can be used to predict EGFR activity in 
the absence of ligand and contributes to the growing mechanistic understanding of the 
EGFR activation process.  
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Figure 6-3. FRET data for the interaction between EGFR and Grb2, under saturating 
ligand conditions. 
(A) In the left-hand plot, FRET efficiency is shown as a function of acceptor 
concentration. In the right-hand plot, we present the ratio between donor concentration 
and acceptor concentration. Each green diamond corresponds to one pair of membrane 
and cytoplasmic regions. (B) The MSE for fits to Equation 6-8 when the number of 
adapter proteins, n, is varied between zero and four. The model with one Grb2 per EGFR 
dimer gives the best fit. (C) The best fit model (yellow surface) and experimental data 
(green diamonds) on linear (left-hand plot) and semi-log (right-hand plot) scales. (D) The 
fraction of receptors found in phosphorylated dimers (red line) and in dimer-adapter 
protein complexes (yellow line) for the best fit model. In the left-hand panel, the adapter 
protein concentration is fixed at 500 proteins/μm3 and the total receptor concentration is 
varied. In the right-hand plot, [T] is fixed at 500 receptors/μm2 and [A] is varied. 
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Figure 6-4. FRET data for the interaction between EGFR and Grb2, in the absence of 
ligand. 
(A) In the left-hand plot, FRET efficiency is shown as a function of acceptor 
concentration and the right-hand plot depicts donor concentration versus acceptor 
concentration, for EGFR-Grb2 experiments in the absence of ligand. We fit Equation 
6-14 to experimental data in order to determine the conformational parameter, β0, 
describing the relationship between inactive and active dimers. (B) The best fit model 
(yellow surface) is plotted alongside experimental data (green diamonds) on both a linear 
(left-hand plot) and semi-log (right-hand plot) scale. (C) fM, fD, fD*, and fD*A are graphed 
as functions of [T] when [A] = 500 proteins/μm3 (left-hand panel) and functions of [A] 
when [T] = 500 receptors/μm2 (right-hand panel). 
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CHAPTER SEVEN Conclusions 
 Recent advances in microscopy have enabled the study of biological systems with 
unprecedented resolution in space and time. In the field of membrane protein research, 
improved microscopy techniques allow for the study of these complex proteins in their 
native environment. In this thesis, I leverage novel quantitative fluorescence microscopy 
techniques to examine RTKs in model membrane systems. I focus on the protein-protein 
interactions involved in the RTK activation process, through the implementation of 
existing protocols and the development of new techniques. My results both support and 
contribute to the emerging model for RTK activation (see Figure 1-1, Panel B).  
 In Chapter Three and Chapter Five, I study unliganded dimers. I contribute to the 
growing body of evidence that wild-type FGFRs can form unliganded homodimers and 
show, for the first time, that wild-type FGFRs can also form unliganded heterodimers. 
Since both FGFR homodimers and heterodimers form with similar propensities, both 
species must be considered in analyses of FGFR functions. This principle may also be 
applicable to other families of RTKs. Additionally, I show that, when FGFRs carry 
certain pathogenic point mutations, both homodimer and heterodimer thermodynamics 
and conformation can be altered. The observed changes in unliganded FGFR dimers 
might contribute to the progression of developmental disorders and should be considered 
during the development of therapeutics.  
 In Chapter Four, I study liganded homodimers. My results indicate that ligand 
addition can induce conformational changes in FGFR homodimers, which supports the 
proposed role of ligand in the emerging model for RTK activation. Additionally, my 
work suggests that homodimer conformation can depend on the identity of the ligand, 
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which  may be one way that receptors differentiate between ligands and generate the 
biological outcomes unique to each ligand. Again, this is a principle of RTK activation 
that might be relevant to other receptors. 
 In Chapter Six, I study the recruitment of an adapter protein to a phosphorylated 
RTK dimer, an event that directly links activated receptors to intracellular signaling 
cascades. I develop a procedure for measuring the thermodynamics of this interaction in 
live cells, and apply it to the interaction between the adapter protein Grb2 and EGFR 
homodimers. Leveraging results obtained in the presence of ligand, I evaluate the 
phosphorylation of the unliganded EGFR dimer and find that approximately one-half of 
unliganded EGFR dimers are phosphorylated. This suggests that, in the emerging model 
for RTK activation, the unliganded dimer species can be an important signaling entity. 
 Overall, thesis work i) illustrates the usefulness of fluorescence microscopy for 
the study of protein-protein interactions and membrane proteins, ii) presents new 
techniques for the study of protein-protein interactions in the plasma membrane, and iii) 
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of live cells, to be used as model membrane systems 
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